



HU000025102T2

(19) **HU****MAGYARORSZÁG**
Szellemi Tulajdon Nemzeti Hivatala(11) Lajstromszám: **E 025 102**(13) **T2****EURÓPAI SZABADALOM**
SZÖVEGÉNEK FORDÍTÁSA(21) Magyar ügyszám: **E 09 719560**(22) A bejelentés napja: **2009. 03. 12.**

(96) Az európai bejelentés bejelentési száma:

EP 20090719560

(97) Az európai bejelentés közzétételi adatai:

EP 2260111 A2 **2009. 09. 17.**

(97) Az európai szabadalom megadásának meghirdetési adatai:

EP 2260111 B1 **2015. 06. 17.**(51) Int. Cl.: **C12Q 1/68** (2006.01)

(86) A nemzetközi (PCT) bejelentési szám:

PCT/US 09/036985

(87) A nemzetközi közzétételi szám:

WO 09114711

(30) Elsőbbségi adatok:

36874	2008. 03. 14.	US
54064	2008. 05. 16.	US

(72) Feltaláló(k):

LACKNER, Mark, Brisbane CA 94044 (US)
AMLER, Lukas, C., Foster City CA 94404 (US)
CAVET, Guy, Burlingame CA 94010 (US)
O'BRIEN, Carol, Pacifica CA 94044 (US)
PANDITA, Ajay, Redwood City CA 94065 (US)

(73) Jogosult(ak):

Genentech, Inc., South San Francisco, CA
94080 (US)

(74) Képviselő:

Frankné dr. Machytka Daisy, Gödölle, Kékes,
Mészáros & Szabó Szabadalmi és Védjegy
Iroda, Budapest

(54)

Hatóanyagrezisztenciához kapcsolódó genetikai variációk

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 260 111 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
17.06.2015 Bulletin 2015/25

(21) Application number: **09719560.6**

(22) Date of filing: **12.03.2009**

(51) Int Cl.:
C12Q 1/68 (2006.01)

(86) International application number:
PCT/US2009/036985

(87) International publication number:
WO 2009/114711 (17.09.2009 Gazette 2009/38)

(54) **GENETIC VARIATIONS ASSOCIATED WITH DRUG RESISTANCE**

MIT RESISTENZ GEGEN ARZNEISTOFFE ASSOZIIERTE GENETISCHE VARIATIONEN

VARIATIONS GÉNÉTIQUES ASSOCIÉES À UNE RÉSISTANCE À DES MÉDICAMENTS

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK TR**
Designated Extension States:
AL BA RS

(30) Priority: **14.03.2008 US 36874**
16.05.2008 US 54064

(43) Date of publication of application:
15.12.2010 Bulletin 2010/50

(73) Proprietor: **Genentech, Inc.**
South San Francisco, CA 94080 (US)

(72) Inventors:

- **LACKNER, Mark**
Brisbane
CA 94044 (US)
- **AMLER, Lukas, C.**
Foster City
CA 94404 (US)
- **CAVET, Guy**
Burlingame
CA 94010 (US)
- **O'BRIEN, Carol**
Pacifica
CA 94044 (US)
- **PANDITA, Ajay**
Redwood City
CA 94065 (US)

(74) Representative: **Walton, Seán Malcolm et al**
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE (GB)

(56) References cited:

WO-A-01/00245 WO-A-03/044215
WO-A-2004/075842 WO-A-2006/074367
US-A1- 2004 101 834 US-A1- 2007 037 228

- **LIU YANG ET AL: "Expression profiling of ABC transporters in a drug-resistant breast cancer cell line using AmpArray" MOLECULAR PHARMACOLOGY, vol. 68, no. 2, August 2005 (2005-08), pages 430-438 URL, XP002544283 ISSN: 0026-895X**
- **NAHTARETAL: "The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 64, no. 7, 1 April 2004 (2004-04-01), pages 2343-2346, XP002378994 ISSN: 0008-5472**
- **O'BRIEN CAROL ET AL: "Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer" CANCER RESEARCH, vol. 68, no. 13, July 2008 (2008-07), pages 5380-5389, XP002544284 ISSN: 0008-5472**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 260 111 B1

Description**FIELD OF THE INVENTION**

5 [0001] The present invention generally relates to genetic variations that are predictive of drug resistance.

BACKGROUND

10 [0002] A key goal of modern molecular oncology is identifying the underlying genetic and genomic variations that characterize a given tumor so that the patient can receive targeted therapy with chemotherapeutic agents likely to provide the most benefit. Breast cancer is the most common form of cancer among women in the Western World, with an estimated 1 million new diagnoses and 400,000 deaths per year worldwide(1). The advent of targeted therapies such as Tamoxifen for estrogen receptor positive cancer (2) and Herceptin for tumors harboring amplification of the HER2 oncogene (3) has had significant impact on patient survival, yet various chemotherapy regimens still form an important component of breast cancer treatment (4). Breast cancer is a heterogeneous disease with distinct molecular subtypes characterized by differential response to targeted and chemotherapeutic agents. While chemotherapy is a successful treatment regimen in many cases, an estimated 50% of patients fail to benefit due to intrinsic or acquired multidrug resistance (1). Multidrug resistance (MDR) refers to the resistance of cancer cells to multiple classes of chemotherapeutic drugs that can be structurally and mechanistically unrelated and is related to the overexpression of a variety of proteins that act as ATP-dependent efflux pumps (5). Understanding the molecular alterations that contribute to MDR in breast cancer is a crucial first step in enabling the development of diagnostic tests capable of predicting resistance to a given therapy and rationally selecting more efficacious therapeutic agents.

15 [0003] ABCC3 Overexpression has been implicated in acquired multidrug resistance in cancer cell lines in previous studies. For instance, Liu et al report 459-fold overexpression of ABC3 relative to the parental in a cell line, MCF-7/AdVp3000, that was derived by selection for growth in the presence of doxorubicin (36). In addition, it has recently been shown that treatment of carcinoma cell lines with vincristine results in significant upregulation of ABCC2 and ABCC3 transcripts in these cells (37). The related pumps ABCC2(MRP2) and ABCC 10 (MRP7) have both been shown to confer paclitaxel resistance when overexpressed (38) (39), and ABCC2 has been shown to be an important determinant of paclitaxel pharmacokinetics in vivo in mouse models (40). Paclitaxel has not been previously demonstrated to be a substrate for ABCC3 and indeed studies of ectopic overexpression of ABCC3 in MDCK or NIH-3T3 cells have failed to demonstrate increased resistance to paclitaxel (41, 42). Notably, it was also found (41) that ABCC3 cannot confer resistance to doxorubicin in long term assays despite other published reports of functional studies suggesting a role for ABCC3 in transporting this agent (36).

20 30 [0004] These various observations illustrate the fact that breast cancer is a heterogeneous disease that can evade chemotherapy through multiple mechanisms and highlight the need for panels of biomarkers that can be used to predict therapeutic response in individual cancer patients.

SUMMARY OF THE INVENTION

40 [0005] One aspect of the present invention provides for a method according to claim 1.

[0006] The amplification of the ABCC3 gene is detected, for example, by determining the copy number of the ABCC3 gene. In some embodiments a copy number of at least 3 indicates ABCC3 gene amplification, in other embodiments, a copy number of at least 5 indicates ABCC3 gene amplification.

45 [0007] The copy number of the ABCC3 gene is determined, for example, by fluorescence in situ hybridization (FISH), Southern Blot, immunohistochemistry (IHC), polymerase chain reaction (qPCR), quantitative PCR (qPCR), quantitative real-time PCR (qRT-PCR), comparative genomic hybridization, microarrays based comparative genomic hybridization, or ligase chain reaction (LCR).

[0008] In one embodiment, Overexpression of the ABC3 gene is detected by determining the level of mRNA transcription from the ABCC3 gene. In some embodiments, overexpression of the ABCC3 gene is indicated by an at least 5-fold increase in mRNA transcription level from the ABCC3 gene in the test cancer sample relative to a control sample. In other embodiments, overexpression of the ABCC3 gene is indicated by an at least 25-fold increase in RNA transcription level from the ABCC3 gene in the test cancer sample relative to a control sample.

50 [0009] In another embodiment, overexpression of the ABC3 gene is detected by determining the level of ABCC3 polypeptide expression. In some embodiments, the level of ABCC3 polypeptide, expression comprises contacting the test cancer sample with an anti-ABCC3 antibody and detecting binding of the anti-ABCC3 antibody to ABC3 polypeptides. In some embodiments, overexpression of the ABCC3 gene is indicated by an at least 2-fold increase in the level of expression of ABCC3 polypeptide in the test cancer sample relative to a control sample. In other embodiments, overexpression of the ABCC3 gene is indicated by an at least 10-fold increase in the level of expression of ABC3 polypeptide

in the test cancer sample relative to a control sample.

[0010] In some embodiments, the anti-mitotic agent is selected from the group consisting of taxanes (including, for example paclitaxel and docetaxel), maytansinoids (including, for example, DM1 and DM4), and auristatins (including, for example, monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF)), and analogs and derivatives thereof.

[0011] In one embodiment, the anti-mitotic agent- antibody conjugate is a maytansinoid- anti-Her2 antibody conjugate, such as trastuzumab-DM1.

[0012] In some embodiments, the breast cancer tumor is a Her-2 positive breast cancer tumor.

[0013] The invention also provides an anti-mitotic agent-antibody conjugate comprising an anti-mitotic agent selected from an auristatin and a maytansinoid covalently linked to an antibody, for use in a method of treating a patient with a breast cancer that is resistant to the anti-mitotic agent-antibody conjugate, the method comprising administering to the patient an antagonist of ABCC3 and the anti-mitotic agent-antibody conjugate, wherein the patient's breast cancer has been determined as resistant to the anti-mitotic agent-antibody conjugate by detecting that ABCC3 gene is amplified or overexpressed in a test breast cancer sample of the patient.

[0014] The invention further provides an antagonist of ABCC3 for use in a method of treating a patient with a breast cancer that is resistant to an anti-mitotic agent-antibody conjugate comprising an anti-mitotic agent selected from an auristatin and a maytansinoid covalently linked to an antibody, the method comprising administering to the patient the antagonist of ABCC3 and the anti-mitotic agent-antibody conjugate, wherein the patient's cancer has been determined as resistant to the anti-mitotic agent-antibody conjugate by detecting that ABCC3 gene is amplified or overexpressed in a test breast cancer sample of the patient.

BRIEF DESCRIPTION OF THE FIGURES

[0015]

Figure 1a illustrates an in vitro response of breast cancer cell lines to MMAE. Figure 1b illustrates an in vitro response of breast cancer cell lines to paclitaxel. On the x-axis, cell lines were classified into major molecular subtypes of breast cancer. The y-axis indicates the in vitro IC50 value, or concentration of drug that resulted in 50% inhibition of cell viability. Horizontal lines indicate mean sensitivity to each agent for cell lines of a given subtype.

Figure 2a shows that in vitro resistance to Paclitaxel is associated with amplification of the Chromosome 17q21 region. Figure 2b shows that in vitro resistance to MMAE is associated with amplification of the Chromosome 17q21 region. Cell lines are shown in order of increasing agent sensitivity from left to right. The classifications (sensitive, intermediate, resistant) used for supervised analysis of SNP array data and identification of biomarkers of resistance are indicated at the top of the figure. Those cell lines with genomic DNA copy number amplification are indicated with a diamond.

Figure 3 shows that ABCC3 is overexpressed in cell lines with 17q21.3 amplification. Thirty-one cell lines were binned into amplified and non-amplified classes based on a copy number cutoff of 4 in the region. Box-and-whisker plots show expression of ABCC3 in each group. 208161 _s_at was selected as the most variable Affymetrix expression probe set representing ABCC3. Other probe sets gave similar results. The central box represents the interquartile range, the line inside the box indicates the median, and the dotted vertical lines extend to the data points furthest from the median but within 1.5 times the interquartile range. Data points outside the dotted vertical lines are represented by individual circles.

Figures 4a-4d show graphs representing mitotic index in response to paclitaxel treatment for four different cell lines after ABCC3 or control siRNA treatment. EFM-192A (a) and ZR-75-30 (b) cells have amplification and overexpression of ABCC3 and display enhanced sensitivity (increased mitotic index) after knockdown whereas HCC-1428 (c) and MDA-MB-453 (d) have low copy number and expression and do not show increased sensitivity.

Figure 5 shows that stable overexpression of ABCC3 results in vitro resistance to paclitaxel and MMAE. Stable cell lines derived from single cell clones that overexpress ABCC3 from the CMV promoter or a control line with empty vector were assayed for growth inhibitory effects of paclitaxel (Figure 5a) or MMAE (Figure 5b).

Figure 6 shows growth inhibition of breast cancer cell lines treated with either MMAE (a) or paclitaxel (b). Points represent the average of four replicate wells in a 384-well plate with fitted nonlinear dose-response curves. The y-axis indicates the percent cell viability relative to control vehicle treated wells. Error bars indicate standard deviations. Figure 7 shows three ABCC3 overexpressing clones and a control cell line analyzed for sensitivity to free DM1 in a standard cell viability assay.

Figure 8 shows a graph representing mitotic index EFM-192A cells transfected with control (NTC) or ABCC3 siRNA when treated with trastuzumab-mc-vc-PAB-MMAF.

Figure 9a shows the mitotic response of EFM-192A cells transfected with control (NTC) or ABCC3 siRNA when treated with free DM1. Figure 9b shows the mitotic response of EFM-192A cells transfected with control (NTC) or ABCC3 siRNA when treated with T-DM1.

Figure 10 shows the result of a FISH analysis performed on samples obtained from a T-DM1 Phase II trial.

Figure 11 is a Table showing information on molecular subtype of cell lines and their sensitivity to anti-mitotic drugs.

DETAILED DESCRIPTION OF EMBODIMENTS

I. DEFINITIONS

[0016] The phrases "gene amplification" and "gene duplication" (and variants such as "amplification of a gene" or "duplication of a gene") are used interchangeably and refer to a process by which multiple copies of a gene or gene fragment are formed in a particular cell or cell line. The duplicated region (a stretch of amplified DNA) is often referred to as an "amplicon." Usually, the amount of the messenger RNA (mRNA) produced, *i.e.*, the level of gene expression, also increases in proportion to the number of copies made of the particular gene.

[0017] The term "ABCC3," as used herein, refers to any native ABCC3 (also known as MRP-3) from any vertebrate source, including mammals such as primates (e.g. humans and monkeys) and rodents (e.g., mice and rats), unless otherwise indicated. The term encompasses "full-length," unprocessed ABCC3 as well as any form of ABCC3 that results from processing in the cell. The term also encompasses naturally occurring variants of ABCC3, e.g., splice variants, allelic variants, and other isoforms. The term also encompasses fragments or variants of a native ABCC3 that maintain at least one biological activity of ABCC3. Examples of ABCC3s include those identified with Genbank accession numbers NM_003786 (human) and XM_358306 (mouse). See also, Kiuchi, et al., FEBS Lett. 433:149-152 (1998); and Borst, et al., JNCI 92(16):1295-1302 (2000).

[0018] The term "genetic variation" includes variations in the amplification of a gene or polypeptide as well as variations in an amino acid sequence or polynucleotide sequence.

[0019] The terms "cell proliferative disorder" and "proliferative disorder" refer to disorders that are associated with some degree of abnormal cell proliferation. In one embodiment, the cell proliferative disorder is cancer.

[0020] "Tumor," as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues. The terms "cancer," "cancerous," "cell proliferative disorder," "proliferative disorder" and "tumor" are not mutually exclusive as referred to herein.

[0021] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth/proliferation. Examples of cancer include, but are not limited to, carcinoma, lymphoma (e.g., Hodgkin's and non-Hodgkin's lymphoma), blastoma, sarcoma, and leukemia. More particular examples of such cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, leukemia and other lymphoproliferative disorders, and various types of head and neck cancer.

[0022] A cancer patient who "responds to treatment" or is "responsive to treatment" with an anti-mitotic is one that shows clinical or therapeutic benefit from or as a result of the treatment with the anti-mitotic agent. Such benefit includes cellular or biological responses, a complete response, a partial response, a stable disease (without progression or relapse), or a response of the patient from or as a result of the treatment with the agent with a later relapse.

[0023] A cancer, cancer cell, or cancer tumor that is "resistant to treatment" with an anti-mitotic agent is one that does not show a statistically significant cellular or biological response to the agent. Conversely, cancer, cancer cells, or cancer tumors that are not resistant to treatment with the agent show statistically significant cellular or biological responses to the agent such as, for example, an increase in the rate of cell death, or apoptosis, or decrease in proliferation or growth as compared to cancer cells or tumors that have not been treated with the agent. In specific embodiments, a cancer, cancer cell, or cancer tumor is resistant to treatment with MMAE if the IC50 is greater than 30 nM, or alternatively greater than 50 nM, or alternatively greater than 100 nM of MMAE. In other embodiments, a cancer, cancer cell, or cancer tumor is resistant to treatment with paclitaxel if the IC50 is greater than 50 nM, or alternatively greater than 100 nM, or alternatively greater than 500 nM, or alternatively greater than 1000 nM of paclitaxel.

[0024] An "anti-mitotic agent" is a compound that inhibits, prevents, or otherwise disrupts mitosis. Specific examples of anti-mitotic agents include, but are not limited to, taxanes, such as paclitaxel and docetaxel; maytansinoids, such as DM1 and DM4; dolastatin 10; dolastatin 15; auristatins, such as monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF); vinca alkaloids, such as vinblastine and vincristine; and analogs and derivatives thereof. The anti-mitotic agent is optionally conjugated to an antibody.

[0025] The terms "treat" or "treatment" refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as the development or spread of cancer. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (*i.e.*, not worsening) state of disease,

delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.

[0026] An "individual" or a "patient" is a vertebrate. In certain embodiments, the vertebrate is a mammal. Mammals include, but are not limited to, farm animals (such as cows), sport animals, pets (such as cats, dogs, and horses), primates, mice and rats. In certain embodiments, a patient is a human.

[0027] An "effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.

[0028] A "therapeutically effective amount" of a substance/molecule of the invention may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the substance/molecule, to elicit a desired response in the individual. A therapeutically effective amount encompasses an amount in which any toxic or detrimental effects of the substance/molecule are outweighed by the therapeutically beneficial effects. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, but not necessarily, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount would be less than the therapeutically effective amount.

[0029] The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents a cellular function and/or causes cell death or destruction. The term is intended to include radioactive isotopes (e.g., At²¹¹, I¹³¹, I¹²⁵, Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³², Pb²¹² and radioactive isotopes of Lu), chemotherapeutic agents (e.g., methotrexate, adriamycin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents, enzymes and fragments thereof such as nucleolytic enzymes, antibiotics, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof, and the various antitumor or anticancer agents disclosed below. Other cytotoxic agents are described below. A "tumoricidal" agent causes destruction of tumor cells.

[0030] A "toxin" is any substance capable of having a detrimental effect on the growth or proliferation of a cell.

[0031] A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer.

[0032] The term "antagonist" is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a polypeptide, such as ABCC3, or the transcription or translation thereof. Suitable antagonist molecules include, but are not limited to, antagonist antibodies, polypeptide fragments, oligopeptides, organic molecules (including small molecules), and anti-sense nucleic acids, including siRNA.

[0033] "Antibodies" (Abs) and "immunoglobulins" (Igs) refer to glycoproteins having similar structural characteristics. While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules which generally lack antigen specificity. Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at increased levels by myelomas.

[0034] The terms "antibody" and "immunoglobulin" are used interchangeably in the broadest sense and include monoclonal antibodies (e.g., full length or intact monoclonal antibodies), polyclonal antibodies, monovalent antibodies, multivalent antibodies, multispecific antibodies (e.g., bispecific antibodies so long as they exhibit the desired biological activity) and may also include certain antibody fragments (as described in greater detail herein). An antibody can be chimeric, human, humanized and/or affinity matured.

[0035] The term "anti-ABCC3 antibody" or "an antibody that binds to ABCC3" refers to an antibody that is capable of binding ABCC3 with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting ABCC3. Preferably, the extent of binding of an anti-ABCC3 antibody to an unrelated, non-ABCC3 protein is less than about 10% of the binding of the antibody to ABCC3 as measured, e.g., by a radioimmunoassay (RIA). In certain embodiments, an antibody that binds to ABCC3 has a dissociation constant (K_d) of < 1 μM, < 100 nM, ≤ 10 nM, ≤ 1 nM, or ≤ 0.1 nM. In certain embodiments, an anti-ABCC3 antibody binds to an epitope of ABCC3 that is conserved among ABCC3 from different species.

[0036] The terms "full length antibody," "intact antibody" and "whole antibody" are used herein interchangeably to refer to an antibody in its substantially intact form, not antibody fragments as defined below. The terms particularly refer to an antibody with heavy chains that contain the Fc region.

[0037] "Antibody fragments" comprise only a portion of an intact antibody, wherein the portion retains at least one, and as many as most or all, of the functions normally associated with that portion when present in an intact antibody. In one embodiment, an antibody fragment comprises an antigen binding site of the intact antibody and thus retains the ability to bind antigen. In another embodiment, an antibody fragment, for example, one that comprises the Fc region, retains at least one of the biological functions normally associated with the Fc region when present in an intact antibody, such as FcRn binding, antibody half life modulation, ADCC function and complement binding. In one embodiment, an antibody fragment is a monovalent antibody that has an *in vivo* half life substantially similar to an intact antibody. For example, such an antibody fragment may comprise an antigen binding arm linked to an Fc sequence capable of conferring *in vivo* stability to the fragment.

[0038] Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an $F(ab')_2$ fragment that has two antigen-combining sites and is still capable of cross-linking antigen.

[0039] "Fv" is a minimum antibody fragment which contains a complete antigen-binding site. In one embodiment, a two-chain Fv species consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. In a single-chain Fv (scFv) species, one heavy- and one light-chain variable domain can be covalently linked by a flexible peptide linker such that the light and heavy chains can associate in a "dimeric" structure analogous to that in a two-chain Fv species. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

[0040] The Fab fragment contains the heavy- and light-chain variable domains and also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. $F(ab')_2$ antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

[0041] "Single-chain Fv" or "scFv" antibody fragments comprise the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain. Generally, the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen binding. For a review of scFv see Pluckthun, in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenberg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).

[0042] The term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) in the same polypeptide chain (VH-VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies may be bivalent or bispecific. Diabodies are described more fully in, for example, EP 404,097; WO93/1161; Hudson et al. (2003) *Nat. Med.* 9:129-134; and Hollinger et al., *Proc. Natl. Acad. Sci. USA* 90: 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al. (2003) *Nat. Med.* 9:129-134.

[0043] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible mutations, e.g., naturally occurring mutations, that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies. In certain embodiments, such a monoclonal antibody typically includes an antibody comprising a polypeptide sequence that binds a target, wherein the target-binding polypeptide sequence was obtained by a process that includes the selection of a single target binding polypeptide sequence from a plurality of polypeptide sequences. For example, the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, or recombinant DNA clones. It should be understood that a selected target binding sequence can be further altered, for example, to improve affinity for the target, to humanize the target binding sequence, to improve its production in cell culture, to reduce its immunogenicity *in vivo*, to create a multispecific antibody, etc., and that an antibody comprising the altered target binding sequence is also a monoclonal antibody of this invention. In contrast to polyclonal antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. In addition to their specificity, monoclonal antibody preparations are advantageous in that they are typically uncontaminated by other immunoglobulins.

[0044] The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including, for example, the hybridoma method (e.g., Kohler et al., *Nature*, 256: 495 (1975); Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981)), recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567), phage display technologies (see, e.g., Clackson et al., *Nature*, 352: 624-628 (1991); Marks et al., *J. Mol. Biol.* 222: 581-597 (1992); Sidhu et al., *J. Mol. Biol.* 338(2): 299-310 (2004); Lee et al., *J. Mol. Biol.* 340(5): 1073-1093 (2004); Fellouse, *Proc. Natl. Acad. Sci. USA* 101(34): 12467-12472 (2004); and Lee et al., *J. Immunol. Methods* 284(1-2): 119-132(2004), and technologies for producing human or human-like antibodies in animals that have parts or all of the human immunoglobulin loci or genes encoding human immunoglobulin sequences (see, e.g., WO98/24893; WO96/34096; WO96/33735; WO91/10741; Jakobovits et al., *Proc. Natl. Acad. Sci. USA* 90: 2551 (1993); Jakobovits et al., *Nature* 362: 255-258 (1993); Bruggemann et al., *Year in Immunol.* 7:33 (1993); U.S. Patent Nos.

5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016; Marks et al., *Bio.Technology* 10: 779-783 (1992); Lonberg et al., *Nature* 368: 856-859 (1994); Morrison, *Nature* 368: 812-813 (1994); Fishwild et al., *Nature Biotechnol.* 14: 845-851 (1996); Neuberger, *Nature Biotechnol.* 14: 826 (1996) and Lonberg and Huszar, *Intern. Rev. Immunol.* 13: 65-93 (1995).

5 **[0045]** The monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; and Morrison et al., *Proc. Natl. Acad. Sci. USA* 81:6851-6855 (1984)).

10 **[0046]** "Humanized" forms of non-human (e.g., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. In one embodiment, a humanized antibody is a human immunoglobulin (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit, or nonhuman primate having the desired specificity, affinity, and/or capacity. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications may be made to further refine antibody performance. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin, and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally will also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., *Nature* 321:522-525 (1986); Riechmann et al., *Nature* 332:323-329 (1988); and Presta, *Curr. Op. Struct. Biol.* 2:593-596 (1992). See also the following review articles and references cited therein: Vaswani and Hamilton, *Ann. Allergy, Asthma & Immunol.* 1:105-115 (1998); Harris, *Biochem. Soc. Transactions* 23:1035-1038 (1995); Hurler and Gross, *Curr. Op. Biotech.* 5:428-433 (1994).

25 **[0047]** A "human antibody" is one which comprises an amino acid sequence corresponding to that of an antibody produced by a human and/or has been made using any of the techniques for making human antibodies as disclosed herein. Such techniques include screening human-derived combinatorial libraries, such as phage display libraries (see, e.g., Marks et al., *J. Mol. Biol.*, 222: 581-597 (1991) and Hoogenboom et al., *Nucl. Acids Res.*, 19: 4133-4137 (1991)); using human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies (see, e.g., Kozbor *J. Immunol.*, 133: 3001 (1984); Brodeur et al., *Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., *J. Immunol.*, 147: 86 (1991)); and generating monoclonal antibodies in transgenic animals (e.g., mice) that are capable of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production (see, e.g., Jakobovits et al., *Proc. Natl. Acad. Sci. USA*, 90: 2551 (1993); Jakobovits et al., *Nature*, 362: 255 (1993); Bruggermann et al., *Year in Immunol.*, 7: 33 (1993)). This definition of a human antibody specifically excludes a humanized antibody comprising antigen-binding residues from a non-human animal.

35 **[0048]** An "affinity matured" antibody is one with one or more alterations in one or more CDRs thereof which result in an improvement in the affinity of the antibody for antigen, compared to a parent antibody which does not possess those alteration(s). In one embodiment, an affinity matured antibody has nanomolar or even picomolar affinities for the target antigen. Affinity matured antibodies are produced by procedures known in the art. Marks et al. *Bio/Technology* 10:779-783 (1992) describes affinity maturation by VH and VL domain shuffling. Random mutagenesis of HVR and/or framework residues is described by: Barbas et al. *Proc Nat. Acad. Sci. USA* 91:3809-3813 (1994); Schier et al. *Gene* 169:147-155 (1995); Yelton et al. *J. Immunol.* 155:1994-2004 (1995); Jackson et al., *J. Immunol.* 154(7):3310-9 (1995); and Hawkins et al., *J. Mol. Biol.* 226:889-896 (1992).

45 **[0049]** A "blocking" antibody or an "antagonist" antibody is one which inhibits or reduces a biological activity of the antigen it binds. Certain blocking antibodies or antagonist antibodies partially or completely inhibit the biological activity of the antigen.

50 **[0050]** Antibody "effector functions" refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody, and vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation.

55 **[0051]** "Fc receptor" or "FcR" describes a receptor that binds to the Fc region of an antibody. In some embodiments, an FcR is a native human FcR. In some embodiments, an FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the Fc γ RI, Fc γ RII, and Fc γ RIII subclasses, including allelic variants and alternatively spliced forms of those receptors. Fc γ RII receptors include Fc γ RIIA (an "activating receptor") and Fc γ RIIB (an "inhibiting receptor"), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. Activating receptor

Fc γ RIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor Fc γ RIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain (see Daëron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed in Ravetch and Kinet, Annu. Rev. Immunol. 9:457-92 (1991); Capel et al., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs, including those to be identified in the future, are encompassed by the term "FcR" herein.

[0052] The term "Fc receptor" or "FcR" also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)) and regulation of homeostasis of immunoglobulins. Methods of measuring binding to FcRn are known. Binding to human FcRn in vivo and serum half life of human FcRn high affinity binding polypeptides can be assayed, e.g., in transgenic mice or transfected human cell lines expressing human FcRn, or in primates administered with Fc variant polypeptides.

[0053] WO00/42072 (Presta) describes antibody variants with improved or diminished binding to FcRs. See, also, Shields et al. J. Biol. Chem. 9(2): 6591-6604 (2001).

[0054] "Human effector cells" are leukocytes which express one or more FcRs and perform effector functions. In certain embodiments, the cells express at least Fc γ RIII and perform ADCC effector function(s). Examples of human leukocytes which mediate ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, cytotoxic T cells and neutrophils. The effector cells may be isolated from a native source, e.g., from blood.

[0055] "Antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of cytotoxicity in which immunoglobulin bound to Fc receptors (FcRs) present on certain cytotoxic effector cells (e.g. Natural Killer (NK) cells, neutrophils, and macrophages) enables those cytotoxic effector cells to bind specifically to an antigen-bearing target cell and subsequently kill the target cell with cytotoxins. The primary cells for mediating ADCC, NK cells, express Fc γ RIII only, whereas monocytes express Fc γ RI, Fc γ RII and Fc γ RIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-92 (1991). To assess ADCC activity of a molecule of interest, an *in vitro* ADCC assay, such as that described in US Patent No. 5,500,362 or 5,821,337 or Presta U.S. Patent No. 6,737,056 may be performed. Useful effector cells for such assays include, peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed *in vivo*, e.g., in an animal model such as that disclosed in Clynes et al. PNAS (USA) 95:652-656(1998).

[0056] "complement dependent cytotoxicity" or "CDC" refers to the lysis of a target cell in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (C1q) to antibodies (of the appropriate subclass) which are bound to their cognate antigen. To assess complement activation, a CDC assay, e.g. as described in Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996), may be performed.

[0057] Polypeptide variants with altered Fc region amino acid sequences and increased or decreased G1q binding capability are described in US Patent No. 6,194,551B1 and WO99/51642. See, also, Idusogie et al. J. Immunol. 164: 4178-4184 (2000).

[0058] The term "Fc region-comprising polypeptide" refers to a polypeptide, such as an antibody or immunoadhesin, which comprises an Fc region. The C-terminal lysine (residue 447 according to the EU numbering system) of the Fc region may be removed, for example, during purification of the polypeptide or by recombinant engineering the nucleic acid encoding the polypeptide. Accordingly, a composition comprising a polypeptide having an Fc region according to this invention can comprises polypeptides with K447, with all K447 removed, or a mixture of polypeptides with and without the K447 residue.

[0059] A "cytotoxic antibody" is an antibody that is capable of an effector function and/or inducing cell death upon binding to its target antigen.

[0060] An "immunoconjugate" or "antibody conjugate" refers to an antibody conjugated to one or more cytotoxic agents.

[0061] A "smart molecule" or "small organic molecule," is defined herein as an organic molecule having a molecular weight below about 500 Daltons.

[0062] An "ABCC3-binding oligopeptide" or an "oligopeptides that binds ABC3" or "ABCC3 polypeptide binding oligopeptide" is an oligopeptide that is capable of binding ABCC3 with sufficient affinity such that the oligopeptides is useful as a diagnostic and/or therapeutic agent in targeting ABC3. In certain embodiments, the extent of binding of an ABCC3-binding oligopeptide to an unrelated, non-ABCC3 protein is less than about 10% of the binding of the ABCC3-binding oligopeptide to ABCC3 as measured, e.g., by a surface plasmon resonance assay. In certain embodiments, an ABCC3-binding oligopeptide has a dissociation constant (Kd) of $\leq 1\mu\text{M}$, $\leq 100\text{ nM}$, $\leq 10\text{ nM}$, $\leq 1\text{ nM}$, or $\leq 0.1\text{ nM}$.

[0063] An "ABCC3-binding organic molecule" or "an organic molecule that binds ABCC3" or "ABCC3 polypeptide binding organic molecule" is an organic molecule other than an oligopeptide or antibody as defined herein that is capable of binding ABCC3 with sufficient affinity such that the organic molecule is useful as a diagnostic and/or therapeutic agent in targeting ABCC3. In certain embodiments, the extent of binding of an FGFR2-binding organic molecule to an unrelated, non ABCC3 protein is less than about 10% of the binding of the ABCC3-binding organic molecule to ABCC3 as measured, e.g., by a surface plasmon resonance assay. In certain embodiments, an ABCC3-binding organic molecule has a dissociation constant (Kd) of $\leq 1\mu\text{M}$, $\leq 100\text{ nM}$, $\leq 10\text{ nM}$, $\leq 1\text{ nM}$, or $\leq 0.1\text{ nM}$.

[0064] The dissociation constant (K_d) of any molecule that binds a target polypeptide may conveniently be measured using a surface plasmon resonance assay. Such assays may employ a BIAcore™-2000 or a BIAcore™-3000 (BIAcore, Inc., Piscataway, NJ) at 25°C with immobilized target polypeptide CM5 chips art~10 response units (RU). Briefly, carboxymethylated dextran biosensor chips (CM5, BIAcore Inc.) are activated with *N*-ethyl-*N'*-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and *N*-hydroxysuccinimide (NHS) according to the supplier's instructions. Target polypeptide is diluted with 10 mM sodium acetate, pH 4.8, to 5 µg/ml (~0.2 µM) before injection at a flow rate of 5 µl/minute to achieve approximately 10 response units (RU) of coupled protein. Following the injection of target polypeptide, 1 M ethanolamine is injected to block unreacted groups. For kinetics measurements, two-fold serial dilutions of the binding molecule (0.78 nM to 500 nM) are injected in PBS with 0.05% Tween 20 (PBST) at 25°C at a flow rate of approximately 25 µl/min. Association rates (k_{on}) and dissociation rates (k_{off}) are calculated using a simple one-to-one Langmuir binding model (BIAcore Evaluation Software version 3.2) by simultaneously fitting the association and dissociation sensorgrams. The equilibrium dissociation constant (K_d) is calculated as the ratio k_{off}/k_{on} . See, e.g., Chen, Y., et al., (1999) J. Mol. Biol. 293:865-881. If the on-rate of an antibody exceeds $10^6 \text{ M}^{-1} \text{ s}^{-1}$ by the surface plasmon resonance assay above, then the on-rate can be determined by using a fluorescent quenching technique that measures the increase or decrease in fluorescence emission intensity (excitation = 295 nm; emission = 340 nm, 16 nm band-pass) at 25°C of a 20 nM antibody (Fab form) in PBS, pH 7.2, in the presence of increasing concentrations of antigen as measured in a spectrometer, such as a stop-flow equipped spectrophotometer (Aviv Instruments) or a 8000-series SLM-Aminco spectrophotometer (ThermoSpectronic) with a stirred cuvette.

[0065] The word "label" when used herein refers to a detectable compound or composition. The label may be detectable by itself (e.g., radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which results in a detectable product. Radionuclides that can serve as detectable labels include, for example, I-131, I-123, I-125, Y-90, Re-188, Re-186, At-211, Cu-67, Bi-212, and Pd-109.

[0066] An "isolated" biological molecule, such as a nucleic acid, polypeptide, or antibody, is one which has been identified and separated and/or recovered from at least one component of its natural environment.

II. DESCRIPTION OF CERTAIN EMBODIMENTS

[0067] Primary breast tumors may be classified into at least three major subtypes by gene expression profiling and the subtypes have different prognostic outcomes in terms of patient survival (9). Luminal breast cancers are typically estrogen receptor positive and characterized by coordinate expression of a number of epithelial specific genes, a relatively good prognosis, and good response rates to targeted hormonal therapies. HER2 positive breast cancers are characterized by high level gene amplification of the HER2 oncogene, relatively poor prognosis if untreated, and significant clinical benefit from the HER2 targeting monoclonal antibody Trastuzumab (Herceptin, Genentech) (3). Basal-like breast cancers typically lack expression of HER2, ER and progesterone receptor and hence are sometimes referred to as "triple negative" tumors (10, 11). Basal-like breast cancers have a relatively poor prognosis and currently have not been shown to respond to any targeted therapy (12). These subtypes display differential response to preoperative chemotherapy regimens (13) but for the most part the drug resistance mechanisms underlying these differences have yet to be determined.

[0068] Recent studies have revealed that large collections of breast cancer cell lines reflect many of the genetic and genomic changes characteristic of human breast tumors and hence may serve as a model system for a population of molecularly heterogeneous breast cancers (14). For instance cells may be classified into basal-like and luminal subtypes based on gene expression profiling signatures, and they retain most of the high-level amplifications and deletions that are associated with poor outcome in primary tumors (14).

[0069] Molecular classification of breast cancers into subtypes with shared features and similar prognostic outcomes provides a framework to begin efforts to individualize cancer therapy. The present invention demonstrates that breast cancer subtypes show clear differences in response to anti-mitotic agents, with the basal-like subtype being the most sensitive. One mechanism for this differential response is amplification of the ABCC3 drug efflux pump that was observed in a subset of luminal and HER2 amplified cell lines but not in basal-like cell lines.

[0070] As described in the Examples, the present invention utilized a panel of breast cancer cell lines molecularly characterized as a model for pharmacogenomic analysis to identify resistance mechanisms and subtype differences in response to two anti-mitotic based therapeutics, monomethyl-auristatin-E (MMAE) and paclitaxel. MMAE is structurally related to dolastatin 10, a pentapeptide natural product that has been the subject of several human clinical trials for cancer therapy, and exhibits potent antitumor activities by inhibiting tubulin polymerization and thus destabilize cellular microtubules (15). Auristatin-monoclonal antibody conjugates have been developed with the rationale that targeted delivery of the drug through specific antigen recognition by the antibody will lead to enhanced chemotherapeutic efficacy while sparing non-target expressing tissues from toxicity (15). Paclitaxel and the related compound docetaxel are anti-cancer cytotoxic drugs that stabilize microtubules and are widely used in the treatment of breast cancer (16).

[0071] Based on these studies set forth in the Examples, amplification of a region of chromosome 17 (17q21) was found to be strongly associated with in vitro resistance to taxanes and auristatins. The region of amplification harbors

at least 100 genes. In order to identify the relevant gene, an unbiased approach consisting of RNA interference and high content analysis was used to show that amplification and concomitant overexpression of the ABCC3 gene is most likely responsible for conferring resistance to paclitaxel and MMAE. It is also shown that this amplicon is present in primary breast tumors and that it is common in HER2 amplified and luminal tumors but not in basal-like cells (Figures 6 and 9).

[0072] Accordingly, one aspect of the invention provides for a method for determining whether a breast cancer in a patient is resistant to treatment with an anti-mitotic agent-antibody conjugate comprising an anti-mitotic agent selected from an auristatin and a maytansinoid covalently linked to an antibody, said method comprising detecting whether the ABCC3 gene is amplified or overexpressed in a test breast cancer sample from the patient, wherein amplification or overexpression of the ABCC3 gene indicates that the breast cancer is resistant to treatment with the anti-mitotic agent-antibody conjugate.

[0073] Gene copy number can be determined by any means known in the art, for example, by fluorescence in situ hybridization (FISH), Southern Blot, immunohistochemistry (IHC), polymerase chain reaction (PCR), quantitative PCR (qPCR), quantitative real-time PCR (qRT-PCR), comparative genomic hybridization, microarray based comparative genomic hybridization, or ligase chain reaction (LCR). See for example, Avison, M., *Measuring Gene Expression*, New York: Taylor & Francis Group, 2007, Allison, D. B., et al, ed. *DNA Microarrays and Related Genomics Techniques: Design, Analysis, and Interpretation of Experiment (Biostatistics)*, Boca Raton : Chapman & Hill/CRC, 2006, Hayat M. A., cd., *Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas*, Burlington: Elsevier Academic Press, 2004.

[0074] Overexpression of the ABCC3 gene indicates that the cancer is resistant to the anti-mitotic agent. Detection of ABCC3 overexpression can be performed by any method known in the art. In one embodiment, ABCC3 gene overexpression is detected by determining the level of mRNA transcription from the ABC3 gene. Levels of mRNA transcription may be determined, either quantitatively or qualitatively, by various methods known to those skilled in the art. Levels of mRNA transcription may also be determined directly or indirectly by detecting levels of cDNA generated from the RNA. Exemplary methods for determining levels of mRNA transcription include, but are not limited to, PCR, real-time quantitative RT-PCR and hybridization-based assays, including microarray-based assays and filter-based assays such as Northern blots. In certain embodiments, the ABCC3 gene is overexpressed if the level of mRNA transcription is at least a 3-, 5-, 7-, 10-, 15-, 20-, 25-, 30-, 35-, 40-, 45-, or 50-fold increase in RNA transcription as compared to an appropriate control sample.

[0075] In other embodiments, expression of the ABCC3 gene is detected by determining the level of ABCC3 polypeptide expression. Levels of ABCC3 polypeptide may be determined, either quantitatively or qualitatively, by certain methods known to those skilled in the art, including antibody-based detection methods. In one embodiment, detecting expression of the ABCC3 gene in a test cancer sample comprises contacting the test cancer sample with an anti-ABCC3 antibody and determining the level of expression (either quantitatively or qualitatively) of ABCC3 in the test cancer sample by detecting binding of the anti-ABCC3 antibody to ABC3 polypeptide. In certain embodiments, binding of an anti-ABCC3 antibody to ABC3 polypeptide may be detected by various methods known to those skilled in the art including, but not limited to, immunohistochemistry, fluorescence activated cell sorting, Western blot, radioimmunoassay, ELISA, and the like. In certain embodiments, overexpression of ABCC3 means at least a 3-, 5-, 7-, 10-, 15-, 20-, 25-, 30-, 35-, 40-, 45-, or 50-fold increase in ABCC3 polypeptide levels as compared to an appropriate control sample.

[0076] A sample of the cancer cells, or test cancer sample, preferably comprises cells taken directly from the cancer tumor, but the test cancer sample can also be comprised of metastatic cancer cells, circulating tumor cells, or any suitable sample of cells that identify the amplifications or expression status of the ABCC3 gene in the cancer.

[0077] Appropriate controls for determining overexpression of ABCC3 in the cancer can be generated, for example, by determining the expression level of ABCC3 in control samples of cells or tissues that express a normal level of ABCC3 and comparing the level of expression of ABCC3 in the cancer to the level of expression of ABCC3 in the control sample. Alternatively, a control can be generated by determining the expression of a housekeeping gene (such as an actin family member) in the same test cancer sample used to determine ABCC3 overexpression, or in a sample from the same cancer to be tested for ABC3 overexpression. The housekeeping gene acts as a comparative control on which to determine overexpression of the ABCC3 gene.

[0078] Detection of ABCC3 amplification and/or overexpression accordingly allows for patients suffering from cancer to select an appropriate method of therapy most likely to successfully treat their cancer.

[0079] In a further embodiment, the patient has Her2 positive breast cancer. Expression or amplification of HER2 in breast cancer (Her2 positive breast cancer) is associated with enhanced clinical benefit from the addition of the anti-mitotic agent paclitaxel after adjuvant treatment with doxorubicin compared to patients with HER2-negative, estrogen-receptor positive, node-positive breast cancer (52). However, a significant fraction of women with HER2-positive tumors fail to show a survival benefit from this treatment (52), suggesting that paclitaxel resistance mechanisms are present in a proportion of HER2 positive breast tumors. This resistance to anti-mitotic agents is of particular concern for therapeutic regimes utilizing anti-Her2 antibodies conjugated to anti-mitotic agents, such as, for example, trastuzumab-DM1 antibody conjugates. As illustrated in the Examples, overexpression of ABCC3 is associated with resistance to treatment with

trastuzumab-anti-mitotic agent conjugates. Conversely, knockdown of the ABCC3 gene with siRNA increases sensitivity of the cells to treatment with trastuzumab-anti-mitotic agent conjugates. Accordingly, the invention provides for methods of selecting a Her2 -positive breast cancer patient for treatment with anti-Her2 antibody-anti-mitotic agent conjugate.

[0080] Also disclosed herein are methods of treating cancer patients based on the ABCC3 amplification status of their cancer. Such a method may comprises detecting whether the ABCC3 gene is amplified in a test cancer sample from the patient and administering to the patient a therapeutically effective amount of an anti-mitotic drug-based chemotherapy if amplification of the ABCC3 gene is not detected in the test cancer sample.

[0081] Another such a method comprises detecting whether the ABCC3 gene is overexpressed in a test cancer sample from the patient and administering to the patient a therapeutically effective amount of an anti-mitotic drug-based chemotherapy if overexpression of the ABCC3 gene is not detected in the test cancer sample. Possibly, the patient has Her2 positive breast cancer and is administered an anti-Her2 antibody-anti-mitotic agent conjugate if amplification or overexpression of the ABCC3 gene is not detected in the test cancer sample. In some approaches, the anti-Her2 antibody-antimitotic agent conjugate is a trastuzumab-anti-mitotic agent conjugate such as trastuzumab-DM1 or trastuzumab-MMAE.

[0082] Possibly, a patient is selected for anti-mitotic drug-based chemotherapy based on absence of ABCC3 amplification or overexpression in their cancer and administered a therapeutically effective amount of an anti-mitotic drug-based chemotherapy. Possibly, the selected patient has Her2 positive breast cancer and is administered an anti-Her2 antibody-anti-mitotic agent conjugate. In some approaches, the anti-Her2 antibody-anti-mitotic agent conjugate is a trastuzumab-anti-mitotic agent conjugate such as trastuzumab-DM1 or trastuzumab-MMAE.

[0083] Also disclosed herein is a method of identifying gene amplification variations that are associated with altered drug sensitivity. Most in vitro profiling efforts directed at understanding drug resistance to date have focused on gene expression analyses. The present disclosure describes the identification of DNA copy number alterations that are associated with altered drug sensitivity through analyses of high density SNP array profiles (Affymetrix). Recent studies have shown that high density single nucleotide polymorphism (SNP) arrays, in addition to their intended application in genotyping, can be used to detect genomic wide DNA copy number changes and loss of heterozygosity in human cancers (17). These arrays have been shown to have applications in the identification of tumor suppressor and oncogene loci by pinpointing recurrently deleted or amplified chromosomal regions (18).

[0084] The data presented herein shows that the arrays can be used to identify amplified regions harboring genes that may modulate the activity of therapeutic drugs. A key advantage of this approach is that gene amplification events are relatively stable and can ultimately be assayed on archival samples from clinical trials. One particularly appropriate assay to detect gene amplification events in the archival samples is fluorescence in situ hybridization (FISH). FISH assays are already part of routine clinical practice in the diagnosis of HER2 positive MBC (50) and are currently being evaluated as diagnostic tests to detect EGFR amplification as a possible biomarker of response to Tarceva or Erbitux (51).

[0085] The disclosure further provides for methods of determining appropriate levels of dosing of an anti-mitotic agent for those patients whose cancers comprise amplification and/or overexpression of ABCC3. Optionally, the method comprises determining whether ABCC3 is amplified and/or overexpressed in a test cancer sample of a patient and administering to the patient an increased dose of anti-mitotic agent if ABCC3 is amplified or overexpressed. The dose of anti-mitotic agent is increased to an amount wherein the cancer shows a response to treatment with an anti-mitotic agent. Optionally, the dose of anti-mitotic agent administered to the patient is at least 1.2 times, or alternatively at least 1.3 times, or alternatively at least 1.5 times, or alternatively at least 2 times, or alternatively at least 2.5 times, or alternatively at least 3 times, or alternatively at least 5 times, or alternatively at least 10 times, the amount administered to a patient whose cancer does not comprise ABCC3 amplification and/or overexpression.

[0086] The disclosure also provides methods of reducing resistance of a cancer cell to an anti-mitotic agent comprising contacting the cancer cell with an antagonist of ABCC3. Possibly, the ABCC3 antagonist serves to prevent amplification and/or overexpression of ABCC3 and decreases the drug resistance conferred by the amplification and/or overexpression. Possibly, the ABCC3 antagonists serve to inhibit ABCC3 activity. Antagonists that are useful in the methods include ABCC3 antibodies, RNA interference (RNAi) based ABCC3 antagonists, especially antisense RNA, mRNA, siRNA, and shRNAs, ABCC3 polypeptide binding oligopeptides, and ABCC3 binding organic molecules.

[0087] The disclosure also provides for a combination therapy for treating a patient with a cancer that is resistant to anti-mitotic agents comprising administering to the patient an antagonist of ABCC3 and an anti-mitotic agent. Optionally, the antagonist is selected from the group consisting of an ABCC3 antibody and an siRNA that binds to ABCC3. Optionally, the anti-mitotic agent is selected from the group consisting of taxanes, maytansinoid, and auristatins, and analogs and derivatives thereof.

[0088] Optionally, the anti-mitotic agent is conjugated to an antibody such as a maytansinoid- anti-Her2 antibody conjugate, for example, trastuzumab-DM1. Optionally, the combination therapy comprises treatment with an siRNA that binds to ABCC3 and trastuzumab-DM1.

[0089] Such combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate formulations), and separate administration, in which case, administration

of an ABCC3 antagonist can occur prior to, simultaneously, and/or following, administration of the anti-mitotic agent.

[0090] Optionally, within the ABCC3 antagonist is an anti-ABCC polypeptide antibody. Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies.

[0091] Polyclonal antibodies are preferably raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and an adjuvant. It may be useful to conjugate the relevant antigen (especially when synthetic peptides are used) to a protein that is immunogenic in the species to be immunized. For example, the antigen can be conjugated to keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor, using a bifunctional or derivatizing agent, e.g., maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl_2 , or $\text{R}^1\text{N}=\text{C}=\text{NR}$, where R and R^1 are different alkyl groups. The animals used to raise antibodies may be transgenic animals. The animals may be engineered such that they exhibit a complete absence of a polynucleotide encoding ABCC3, such that they have no ABCC3 expression (referred to as "knockout" animals). Methods of generating such animals are well-known in the art, see, e.g., Snouwaert et al., *Science* 257:1083, 1992; Lowell et al., *Nature* 366:740-42, 1993; Capecchi, M. R., *Science* 244: 1288-1292, 1989. Raising antibodies to a particular protein or peptide in a knockout animal for that protein or peptide may be advantageous because anti-self reactions in the animal that may reduce production and/or yields of the antibody should not occur, as is well known in the art.

[0092] Animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining, e.g., 100 μg or 5 μg of the protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later, the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later, the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response.

[0093] Monoclonal antibodies may be made using the hybridoma method first described by Kohler et al., *Nature*, 256:495 (1975), or may be made by recombinant DNA methods (U.S. Patent No. 4,816,567).

[0094] The anti-ABCC3 antibodies employed may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')_2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-329 (1988); and Presta, *Curr. Op. Struct. Biol.*, 2:593-596 (1992)].

[0095] Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeven et al., *Science*, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

[0096] The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity and HAMA response (human anti-mouse antibody) when the antibody is intended for human therapeutic use. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable domain sequences. The human V domain sequence which is closest to that of the rodent is identified and the human framework region (FR) within it accepted for the humanized antibody (Sims et al., *J. Immunol.* 151:2296 (1993); Chothia et al., *J. Mol. Biol.*, 196:901 (1987)). Another method uses a particular framework region derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter et al., *Proc. Natl. Acad. Sci. USA*, 89:4285 (1992); Presta et al., *J. Immunol.* 151:2623 (1993)).

[0097] It is further important that antibodies be humanized with retention of high binding affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the hypervariable region residues are directly and most substantially involved in influencing antigen binding.

[0098] Various forms of a humanized anti-ABCC3 polypeptide antibody are contemplated. For example, the humanized antibody may be an antibody fragment, such as a Fab, which is optionally conjugated with one or more cytotoxic agent(s) in order to generate an immunoconjugate. Alternatively, the humanized antibody may be an intact antibody, such as an intact IgG1 antibody.

[0099] As an alternative to humanization, human antibodies can be generated. For example, it is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining region (J_H) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array into such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggemann et al., Year in Immuno. 7:33 (1993); U.S. Patent Nos. 5,545,806, 5,569,825, 5,591,669 (all of GenPharm); 5,545,807; and WO 97/17852.

[0100] Alternatively, phage display technology (McCafferty et al., Nature 348:552-553 [1990]) can be used to produce human antibodies and antibody fragments *in vitro*, from immunoglobulin variable (V) domain gene repertoires from unimmunized donors. According to this technique, antibody V domain genes are cloned in-frame into either a major or minor coat protein gene of a filamentous bacteriophage, such as M 13 or fd, and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous particle contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties. Thus, the phage mimics some of the properties of the B-cell. Phage display can be performed in a variety of formats, reviewed in, e.g., Johnson, Kevin S. and Chiswell, David J., Current Opinion in Structural Biology 3:564-571 (1993). Several sources of V-gene segments can be used for phage display. Clackson et al., Nature, 352:624-628 (1991) isolated a diverse array of anti-oxazolone antibodies from a small random combinatorial library of V genes derived from the spleens of immunized mice. A repertoire of V genes from unimmunized human donors can be constructed and antibodies to a diverse array of antigens (including self-antigens) can be isolated essentially following the techniques described by Marks et al., J. Mol. Biol. 222:581-597 (1991), or Griffith et al., EMBO J. 12:725-734 (1993). See, also, U.S. Patent Nos. 5,565,332 and 5,573,905.

[0101] As discussed above, human antibodies may also be generated by *in vitro* activated B cells (see U.S. Patents 5,567,610 and 5,229,275).

[0102] In certain circumstances there are advantages of using antibody fragments, rather than whole antibodies. The smaller size of the fragments allows for rapid clearance, and may lead to improved access to solid tumors.

[0103] Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117 (1992); and Brennan et al., Science, 229:81 (1985)). However, these fragments can now be produced directly by recombinant host cells. Fab, Fv and ScFv antibody fragments can all be expressed in and secreted from *E. coli*, thus allowing the facile production of large amounts of these fragments. Antibody fragments can be isolated from the antibody phage libraries discussed above. Alternatively, Fab'-SH fragments can be directly recovered from *E. coli* and chemically coupled to form $F(ab')_2$ fragments (Carter et al., Bio/Technology 10:163-167 (1992)). According to another approach, $F(ab')_2$ fragments can be isolated directly from recombinant host cell culture. Fab and $F(ab')_2$ fragment with increased *in vivo* half-life comprising a salvage receptor binding epitope residues are described in U.S. Patent No. 5,869,046. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner. In other embodiments, the antibody of choice is a single chain Fv fragment (scFv). See WO 93/16185; U.S. Patent No. 5,571,894; and U.S. Patent No. 5,587,458. Fv and sFv are the only species with intact combining sites that are devoid of constant regions; thus, they are suitable for reduced nonspecific binding during *in vivo* use. sFv fusion proteins may be constructed to yield fusion of an effector protein at either the amino or the carboxy terminus of an sFv. See Antibody Engineering, ed. Borrebaeck, supra. The antibody fragment may also be a "linear antibody", e.g., as described in U.S. Patent 5,641,870 for example. Such linear antibody fragments may be monospecific or bispecific.

[0104] It may be desirable to modify the antibody with respect to effector function, e.g., so as to enhance antigen-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) of the antibody. This may be achieved by introducing one or more amino acid substitutions in an Fc region of the antibody. Alternatively or additionally, cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med. 176:1191-1195 (1992) and Shopes, B. J. Immunol. 148:2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff et al., Cancer Research 53:2560-2565 (1993). Alternatively, an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., AntiCancer Drug Design 3:219-230 (1989). To increase the serum half life of the antibody, one may incorporate a salvage receptor binding epitope into the antibody (especially an antibody fragment) as described in U.S. Patent 5,739,277, for example. As used herein, the term "salvage receptor binding epitope" refers to an epitope of the Fc region of an IgG molecule (e.g., IgG₁, IgG₂, IgG₃, or IgG₄) that is responsible for increasing the *in vivo* serum half-life of the IgG molecule.

[0105] Another potential ABCC3 antagonist is an antisense RNA or DNA construct prepared using antisense technology, where, e.g., an antisense RNA or DNA molecule acts to block directly the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes the mature ABCC3 polypeptide herein, can be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res., 6:3073 (1979); Cooney et al., Science, 241: 456 (1988); Dervan et al., Science, 251:1360 (1991)), thereby preventing transcription and the production of the ABCC3 polypeptide. The antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into the ABCC3 polypeptide (antisense - Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression (CRC Press: Boca Raton, FL, 1988). The oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed *in vivo* to inhibit production of the ABCC3 polypeptide. When antisense DNA is used, oligodeoxyribonucleotides derived from the translation-initiation site, e.g., between about -10 and +10 positions of the target gene nucleotide sequence, are preferred.

[0106] Small interfering RNAs (siRNAs) are double stranded RNA molecules generally less than 30 nucleotides in length that reduce expression of a target gene. siRNAs have proven useful as a tool in studies of modulating gene expression where traditional antagonists such as small molecules or antibodies have failed. (Shi Y., Trends in Genetics 19(1):9-12 (2003)). *In vitro* synthesized, double stranded RNAs that are 21 to 23 nucleotides in length can act as interfering RNAs (iRNAs) and can specifically inhibit gene expression (Fire A., Trends in Genetics 391; 806-810 (1999)). These iRNAs act by mediating degradation of their target RNAs. Since they are under 30 nucleotides in length, however they do not trigger a cell antiviral defense mechanism. In some embodiments of the invention, the siRNA has at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% nucleic acid sequence identity with a portion of the coding sequence of the ABCC3 encoding polynucleotide or its complement.

[0107] ABCC3 polypeptide binding oligopeptides are oligopeptides that bind, preferably specifically, to an ABCC3 polypeptide as described herein. ABCC3 polypeptide binding oligopeptides may be chemically synthesized using known oligopeptide synthesis methodologies or may be prepared and purified using recombinant technology. ABCC3 polypeptide binding oligopeptides are usually at least about 5 amino acids in length, alternatively at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 amino acids in length or more, wherein such oligopeptides that are capable of binding, preferably specifically, to a ABCC3 polypeptide as described herein. ABCC3 polypeptide binding oligopeptides may be identified without undue experimentation using well known techniques. In this regard, it is noted that techniques for screening oligopeptide libraries for oligopeptides that are capable of specifically binding to a polypeptide target are well known in the art (see, e.g., U.S. Patent Nos. 5,556,762, 5,750,373, 4,708,871, 4,833,092, 5,223,409, 5,403,484, 5,571,689, 5,663,143; PCT Publication Nos. WO 84/03506 and WO84/03564; Geysen et al., Proc. Natl. Acad. Sci. U.S.A., 81:3998-4002 (1984); Geysen et al., Proc. Natl. Acad. Sci. U.S.A., 82:178-182 (1985); Geysen et al., in Synthetic Peptides as Antigens, 130-149 (1986); Geysen et al., J. Immunol. Meth., 102:259-274 (1987); Schoofs et al., J. Immunol., 140:611-616 (1988), Cwirla, S. E. et al. (1990) Proc. Natl. Acad. Sci. USA, 87:6378; Lowman, H.B. et al. (1991) Biochemistry, 30:10832; Clackson, T. et al. (1991) Nature, 352: 624; Marks, J. D. et al. (1991), J. Mol. Biol., 222:581; Kang, A.S. et al. (1991) Proc. Natl. Acad. Sci. USA, 88:8363, and Smith, G. P. (1991) Current Opin. Biotechnol., 2:668).

[0108] In this regard, bacteriophage (phage) display is one well known technique which allows one to screen large oligopeptide libraries to identify member(s) of those libraries which are capable of specifically binding to a polypeptide

target. Phage display is a technique by which variant polypeptides are displayed as fusion proteins to the coat protein on the surface of bacteriophage particles (Scott, J.K. and Smith, G. P. (1990) *Science*, 249: 386). The utility of phage display lies in the fact that large libraries of selectively randomized protein variants (or randomly cloned cDNAs) can be rapidly and efficiently sorted for those sequences that bind to a target molecule with high affinity. Display of peptide (Cwirla, S. E. et al. (1990) *Proc. Natl. Acad. Sci. USA*, 87:6378) or protein (Lowman, H.B. et al. (1991) *Biochemistry*, 30:10832; Clackson, T. et al. (1991) *Nature*, 352: 624; Marks, J. D. et al. (1991), *J. Mol. Biol.*, 222:581; Kang, A.S. et al. (1991) *Proc. Natl. Acad. Sci. USA*, 88:8363) libraries on phage have been used for screening millions of polypeptides or oligopeptides for ones with specific binding properties (Smith, G. P. (1991) *Current Opin. Biotechnol.*, 2:668). Sorting phage libraries of random mutants requires a strategy for constructing and propagating a large number of variants, a procedure for affinity purification using the target receptor, and a means of evaluating the results of binding enrichments. U.S. Patent Nos. 5,223,409, 5,403,484, 5,571,689, and 5,663,143.

[0109] Methods of generating peptide libraries and screening these libraries are also disclosed in U.S. Patent Nos. 5,723,286, 5,432,018, 5,580,717, 5,427,908, 5,498,530, 5,770,434, 5,734,018, 5,698,426, 5,763,192, and 5,723,323.

[0110] ABCC3 polypeptide binding small molecules are preferably organic molecules other than oligopeptides or antibodies as defined herein that bind, preferably specifically, to an ABCC3 polypeptide as described herein. ABCC3 polypeptide binding organic small molecules may be identified and chemically synthesized using known methodology (see, e.g., PCT Publication Nos. WO00/00823 and WO00/39585). ABCC3 polypeptide binding organic small molecules are usually less than about 2000 daltons in size, alternatively less than about 1500, 750, 500, 250 or 200 daltons in size, wherein such organic small molecules that are capable of binding, preferably specifically, to a ABCC3 polypeptide as described herein may be identified without undue experimentation using well known techniques. In this regard, it is noted that techniques for screening organic small molecule libraries for molecules that are capable of binding to a polypeptide target are well known in the art (see, e.g., PCT Publication Nos. WO00/00823 and WO00/39585). ABCC3 polypeptide binding organic small molecules may be, for example, aldehydes, ketones, oximes, hydrazones, semicarbazones, carbazides, primary amines, secondary amines, tertiary amines, N-substituted hydrazines, hydrazides, alcohols, ethers, thiols, thioethers, disulfides, carboxylic acids, esters, amides, ureas, carbamates, carbonates, ketals, thioketals, acetals, thioacetals, aryl halides, aryl sulfonates, alkyl halides, alkyl sulfonates, aromatic compounds, heterocyclic compounds, anilines, alkenes, alkynes, diols, amino alcohols, oxazolidines, oxazolines, thiazolidines, thiazolines, enamines, sulfonamides, epoxides, aziridines, isocyanates, sulfonyl chlorides, diazo compounds, acid chlorides, or the like.

[0111] Pharmaceutical formulations comprising any of the above agents are prepared for storage by mixing the antibody or immunoconjugate having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's *Pharmaceutical Sciences* 16th edition, Osol, A. Ed. (1980)) in the form of aqueous solutions or lyophilized or other dried formulations. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, histidine and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride); phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG). Pharmaceutical formulations to be used for *in vivo* administration are generally sterile. This is readily accomplished by filtration through sterile filtration membranes.

[0112] An agent may also be entrapped in microcapsule prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsule and poly-(methylmethacrylate) microcapsule, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's *Pharmaceutical Sciences* 16th edition, Osol, A. Ed. (1980).

[0113] Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the agent of interest, which matrices are in the form of shaped articles, e.g., films, or microcapsule. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated agents remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and, for antibodies, possible changes in immu-

nogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

Anti-mitotic agents

[0114] An anti-mitotic agent is any compound that inhibits, prevents, or otherwise disrupts mitosis. Specific examples of anti-mitotic agents include, but are not limited to, taxanes, such as paclitaxel and docetaxel; maytansinoids, including maytansinol and maytansinol analogues modified in the aromatic ring or at other positions of the maytansinol molecule, such as various maytansinol esters, and DM1 and DM4; dolastatin 10, dolastatin 15, and auristatins, such as monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF); vinca alkaloids, such as vinblastine and vincristine; and analogs and derivatives thereof.

[0115] The taxanes are anticancer drugs both derived from the yew tree. Docetaxel (TAXOTERE®, Rhone-Poulenc Rorer), derived from the European yew, is a semisynthetic analogue of paclitaxel (TAXOL®, Bristol-Myers Squibb). Paclitaxel and docetaxel promote the assembly of microtubules from tubulin dimers and stabilize microtubules by preventing depolymerization, which results in the inhibition of mitosis in cells.

[0116] Maytansinoids are tubulin-binding agents that are potent anti-mitotics, causing cells to arrest in the G2/M phase of the cell cycle and ultimately leading to cell death. Maytansinoids are derivatives of the maytansine, a compound first isolated from the east African shrub *Maytenus serrata* (U.S. Pat. No. 3,896,111). Subsequently, it was discovered that certain microbes also produce maytansinoids, such as maytansinol and C-3 maytansinol esters (U.S. Pat. No. 4,151,042). Synthetic maytansinol and maytansinol analogues have been reported. See U.S. Pat. Nos. 4,137,230; 4,248,870; 4,256,746; 4,260,608; 4,265,814; 4,294,757; 4,307,016; 4,308,268; 4,308,269; 4,309,428; 4,313,946; 4,315,929; 4,317,821; 4,322,348; 4,331,598; 4,361,650; 4,364,866; 4,424,219; 4,450,254; 4,362,663; and 4,371,533, and Kawai et al (1984) Chem. Pharm. Bull. 3441-3451).

[0117] The auristatins are analogs of dolastatin 10 (a pentapeptide natural product), including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF). Molecules in this family inhibit tubulin polymerization. In general, the activities are 100-1,000 times more potent than doxorubicin. (Pettit, G. R., The dolastatins. Progress in the Chemistry of Organic Natural Products 70, 1-79, 1997).

[0118] The anti-mitotic agent is optionally conjugated to an antibody.


[0119] There are many linking groups known in the art for making antibody-agent conjugates. Antibody- maytansinoid conjugates have been widely described in the literature. See, for example, U.S. Patent No. 5,208,020 or EP Patent 0 425 235 B1, and Chari et al., Cancer Research 52:127-131 (1992). The linking groups useful for making antibody-agent conjugates include disulfide groups, thioether groups, acid labile groups, photolabile groups, peptidase labile groups, or esterase labile groups, as disclosed in the above-identified patents, disulfide and thioether groups being preferred.

[0120] Conjugates of the antibody and maytansinoid, or other anti-mitotic agent, may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate, iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). Particularly preferred coupling agents include N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP) (Carlsson et al., Biochem. J. 173:723-737 [1978]) and N-succinimidyl-4-(2-pyridylthio)pentanoate (SPP) to provide for a disulfide linkage.

[0121] The linker may be attached to the maytansinoid molecule at various positions, depending on the type of the link. For example, an ester linkage may be formed by reaction with a hydroxyl group using conventional coupling techniques. The reaction may occur at the C-3 position having a hydroxyl group, the C-14 position modified with hydroxymethyl, the C-15 position modified with a hydroxyl group, and the C-20 position having a hydroxyl group. In one embodiment, the linkage is formed at the C-3 position of maytansinol or a maytansinol analogue.

[0122] Examples of anti-mitotic-antibody conjugates include, but are not limited to, trastuzumab-DM1 (Genentech/ImmunoGen, described in US Patent 7,097,840), Trastuzumab-auristatin (Genentech/ Seattle Genetics), Cantuzumab mertansine (huC242- DM1, SB-408075) (ImmunoGen), BB-10901 (huN901-DM1) (ImmunoGen), MLN2704(DM 1) (Millennium Pharmaceuticals), Bivatuzumab mertansine (DM1) (Boehringer Ingelheim), huMy9-6-DM4 (AVE9633) (Sanofi-aventis), huC242-DM4 (ImmunoGen), SGN-35 (Monomethyl auristatin) (Seattle Genetics), SGN-75 (Monomethyl auristatin) (Seattle Genetics), and CR011-vcMMAE (Curagen/Seattle Genetics). Lambert, J.M., et al, Current Opinion in Pharmacology, 5:543-549 (2005). See also US20050276812, WO2004110498, Wul, A. M., and Senter, P. D., Nature Biotech 23: 1137 - 1146 (2005).

[0123] Trastuzumab-MCC-DM1 (T-DM1) (CAS Reg. No. 139504-50-0) has the structure:



where Tr is trastuzumab, linked through linker moiety MCC, to the maytansinoid drug moiety, DM1 (US 5208020; US 6441163). The drug to antibody ratio or drug loading is represented by p in the above structure of trastuzumab-MCC-DM1, and ranges in integer values from 1 to about 8. The drug loading value p is 1 to 8. Trastuzumab-MCC-DM1 includes all mixtures of variously loaded and attached antibody-drug conjugates where 1, 2, 3, 4, 5, 6, 7, and 8 drug moieties are covalently attached to the antibody trastuzumab (US 7097840; US 2005/0276812; US 2005/0166993). Trastuzumab is an antibody that has antigen binding residues of, or derived from, the murine 4D5 antibody (ATCC CRL 10463, deposited with American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852 under the Budapest Treaty on May 24, 1990). Exemplary humanized 4D5 antibodies include huMAb4D5-1, huMAb4D5-2, huMAb4D5-3, huMAb4D5-4, huMAb4D5-5, huMAb4D5-6, huMAb4D5-7 and huMAb4D5-8 (HERCEPTIN®) as in US 5821337.

[0124] Trastuzumab -DM1 (or T-DM1) has been shown to be efficacious in trastuzumab-sensitive and trastuzumab-insensitive models of HER2-overexpressing cancer. Clinical studies are currently under way to assess the safety and efficacy of T-DM1 in patients with HER2-overexpressing breast cancer.

EXAMPLES

Example 1 - Techniques and Assays

Cell Lines and Viability Experiments

[0125] Breast cancer cell lines AU565, BT-474, BT-549, CAMA-1, DU4475, HCC1143, HCC1419, HCC1428, HCC2218, HCC70, Hs578T, KPL-1, MCF-7, MDA-MB-231, MDA-MB-435S, MDA-MB-436, MDA-MB-453, MDA-MB-468, T-47D, UACC-812, ZR-75-1 and ZR-75-30 were obtained from American Type Culture Collection (ATCC, Manassas, VA). The cell lines CAL-120, CAL-148, CAL-51, CAL-85-1, EFM-19, EFM-192A, EVSA-T, and MT-3 were obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ, Braunschweig, Germany). All cell lines were maintained in RPMI 1640 or DMEM supplemented with 10% fetal bovine serum (Sigma, St. Louis, MO), non-essential amino acids and 2 mmol/L L-glutamine. Though annotated as breast lines, MDA-MB-435S may actually be of melanoma origin and MT-3 of colorectal origin based on molecular and genetic criteria (19, 20). These findings do not impact the conclusions of this study.

[0126] For MMAE and paclitaxel IC₅₀ determination, cells were plated in quadruplicate at a density of 3000 cells per well in 384-well plates in normal growth medium and allowed to adhere overnight. Paclitaxel (Sigma) or MMAE (Seattle Genetics, Seattle, WA) were added in 10 concentrations based on a three-fold dilution series (1 μmol/L maximal paclitaxel or 0.1 μmol/L maximal for MMAE).

[0127] Cell viability was measured 72 hours later using the Celltiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI). The concentration of drug resulting in the 50% inhibition of cell viability (IC₅₀) was calculated from a four-parameter curve analysis (XLfit, IDBS software) and was determined from a minimum of three experiments. Cell lines that did not show 50% reduction in cell viability in response to drug treatment in the majority of experiments conducted were considered to not have reached an IC₅₀ by definition and are listed as having an IC₅₀ of >100nM (MMAE) or >1000nM (paclitaxel). Figure 6 provides examples of representative cell viability experiments for six cell lines. Cell lines EFM192A, NDAMB361, and BT474 were classified as resistant to each agent in the bioinformatic analysis. AU565, EFM19, and MDAMB468 were classified as sensitive. IC₅₀ values from fitted curves are shown in the charts to the right of each graph.

[0128] For ABCC3-overexpressing clones of the EVSA-T cell line that did not achieve IC50, we calculated the half-maximal effect concentration, or EC50, in GraphPad Prism software (GraphPad Software, Inc). The control cell line in Figure 5 is in fact a clone of EVSA-T derived after transfection with an empty vector and in the particular experiment shown achieved an IC50.

Breast tumor samples

[0129] Primary breast tumors from 145 independent breast cancer patients were utilized to make genomic DNA for Agilent Array CGH analysis (21). All the tumors were fresh frozen and found to have greater than 70% tumor content, and all were classified as infiltrating ductal carcinoma. ABCC3 FISH studies were conducted on 61 additional independent primary breast tumor samples from the Genentech tumor bank.

Gene Expression Microarray Studies

[0130] Gene expression analysis of breast cancer cell lines was carried out on RNA extracted from sub-confluent cell cultures using Qiagen RNeasy kits. RNA quality was verified by running samples on an Agilent Bioanalyzer 2100 and samples of sufficient quality were profiled on Affymetrix HGU133Plus_2.0 chips (Santa Clara, CA). Preparation of complementary RNA, array hybridizations, scanning and subsequent array image data analysis were done using the manufacturer's specified protocol.

[0131] For overall unsupervised hierarchical clustering analysis of breast cancer cell lines, gene expression data were filtered to remove probe sets that showed little variation across the cell lines. Briefly, probes that did not show at least a five fold variation across the samples (max/min>10) and an absolute intensity difference of at least 250 (max-min>250) were excluded from hierarchical clustering analysis. Data preprocessing involved log transforming and median centering gene expression values, after which average linkage clustering was carried out using Cluster and TreeView software (22).

SNP Array and Agilent aCGH Copy Number Studies

[0132] Cell line copy number analysis was carried out on genomic DNA extracted from sub-confluent cell cultures using Qiagen DNAeasy kits. For each cell line 500 ng of genomic DNA was hybridized to Genechip 100K mapping arrays (Affymetrix, Inc., Santa Clara, CA) according to the manufacturer's instructions. These arrays contain probe sets for more than 116,000 SNP loci derived from all human chromosomes (except the Y chromosome), with a mean marker distance of 26 kb (23). SNP calls and signal quantification were obtained with Gene Chip Operating System. Agilent Human Genome 244A CGH microarrays and Agilent feature extraction software were run according to the manufacturer's instructions and Genome-smoothed analysis DNA copy number (GSA_CN) was calculated based on the hybridization intensity (the sum of both allele intensities) for each SNP probe with the Affymetrix Chromosome Copy Number Analysis Tool 3.0 (CNAT 3.0). Copy number data were segmented with the GLAD segmentation algorithm (24).

[0133] Associations between GSA_CN copy number and drug sensitivity were identified with Matlab software (The MathWorks, Inc. Natick, MA, USA) using a version of the maxT procedure (26). For each drug, a test statistic was calculated for each SNP reflecting the difference between log-transformed copy number in sensitive and resistant cell lines. The statistic was calculated as the absolute value of a standard t statistic (two sample, unequal variance), except that it was set to zero for those SNPs with less than 1.75-fold difference in mean copy number between sensitive and resistant classes. Then the null distribution of maximum test statistics across all SNPs was estimated in 10,000 random permutations of the sensitivity labels. The p-value for each SNP was calculated as the fraction of permutations in which the maximum test statistic was greater than or equal to the observed statistic for that SNP. The resulting p-values control the family-wise error rate and take into account the number of SNPs tested.

HER2 copy number determination by Quantitative RT PCR

[0134] Quantitative PCR was performed using ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA) on genomic DNA prepared as described above. qRT-PCR was performed using primers CACTGTCT-GCACCTTGCTTTG (SEQ ID NO: 1) and GCTCTGCAGCTATTGAAAGAACAA (SEQ ID NO: 2) for Her 2 and AAAGCCGCTCAACTACATGG (SEQ ID NO:3) and TGCTTTGAATGCGTCCCAGAG (SEQ ID NO: 4) for Line-1 repetitive elements. Line-1 is a repetitive element with similar copy numbers per haploid genome between human normal and neoplastic cells (27). Quantification was based on standard curves from a serial dilution of human normal genomic DNA. The relative target copy number level was also normalized to normal human genomic DNA as calibrator. Copy number change of target gene relative to the Line-1 and the calibrator were determined using the formula $E^{-[(C_{Ptarget} - C_{pref})_{control} - (C_{Ptarget} - C_{pref})_{test}]}$ as described by Kindich et al (28). Conditions for quantitative PCR reaction were

as described in the Invitrogen Platinum® SYBR® Green qPCR SuperMix-UDG w/ROX package insert (catalog number 11744-500).

Fluorescence in situ hybridization (FISH) Analysis

Probes

[0135] A bacterial artificial chromosome (BAC) contig comprising of 2 overlapping clones, CTD -2605A1 and CTD-3006C13, covering the entire ABCC3 loci and adjoining areas (based on the USCS Genome Browser March 2006 assembly) were used as a probe for the FISH experiments. Commercially available probes for HER2/CEP 17 (Pathvysion, Vysis/Abbott Laboratories, Des Plaines, IL) and CEP17 (Vysis/Abbott Laboratories, Des Plaines, IL) were also used for the FISH experiments.

FISH Analysis

[0136] Cell lines were prepared for cytogenetic analysis by incubation with 0.1 µg/mL Colcemid (Invitrogen) for 2-3 h, followed by osmotic swelling in KCl (0.075 M) and fixation in methanol: acetic acid (3:1), as previously described (29). DNA from the BAC clones was extracted by standard methods.

[0137] The extracted BAC DNA was directly labeled with Spectrum Orange, Spectrum Green, (Vysis/Abbott Laboratories, Des Plaines, IL) or diethylaminocoumarin (DEAC) (Invitrogen) by nick translation using the Vysis Nick Translation Kit (Vysis/Abbott Laboratories) according to the manufacturer's instructions. FISH to normal human metaphases (Abbott Laboratories, Des Plaines, IL) confirmed the genomic location of the BAC clones. Approximately 300 ng of labeled probes were precipitated in excess Human Cot-1 DNA (Invitrogen) and sonicated salmon sperm DNA (Sigma) and resuspended in a 50% formamide, 10% dextran sulfate, and 2' SSC hybridization buffer (Vysis/Abbott Laboratories, Des Plaines, IL) for the FISH experiments. FISH on cytogenetic preparations and formalin fixed paraffin embedded (FFPE) tissue was performed as described previously (Pandita et al., 2004), with some modifications. After an overnight incubation at 56° - 60 ° C, the slides were deparaffinized in 3 washes of CitroSolv for 5 min each, followed by two washes in alcohol. After air-drying, the slides were incubated in a 1M solution of NaSCN for 30 min at 80°C and then were treated with pepsin prior to additional washes in water and a series of ethanol. Dried slides were then co-denatured (76°C for 6 min) with the probe and were hybridized overnight at 37°C (ThermoBrite; Vysis, Downers Grove, IL). Post-hybridization washes and counter-staining were done in a manner similar to those previously described. The slides were visualized using an Olympus BX61 microscope and analyzed using FISHView software (Applied Spectral Imaging, Vista CA). The copy number analysis and ratio of HER2/ABCC3 to CEP 17 was performed as per the manufacturer's instructions.

Functional validation experiments

[0138] High content screening assays were carried out on an Arrayscan VTI (Cellomics Inc, Pittsburgh, PA). Cells were transfected in 96 well format using siRNA "Smartpool" oligonucleotides purchased from Dharmacon Inc and Oligofectamine transfection reagents. To prioritize genes for functional studies, 2-sided Wilcoxon rank sum tests using the R programming language (<http://www.r-project.org>) were done to identify genes with a significant difference in gene expression in cell lines with more than 4 copies compared to those with less than 4 copies of the 17q21.3 amplicon. An example of differential expression for gene that emerged from this analysis, ABCC3 (p=0.0053) is shown in Figure 3. This analysis combined with availability of reagents for RNAi experiments led to the selection of the following 24 genes for functional studies in the EFM-192A cell line: ABCC3, COL1A1, CROP, EAP, EPN3, FLJ13855, FLJ20920, HOXB7, LOC201191, ITGB3, KIAA0924, KPNB1, LOC400604, LOC81558, MGC11242, MGC15396, NDP52, PDK2, PHB, PP1R9B, SLC35B1, SPOP, TOB1, WNT3. Follow-up studies with ABCC3 siRNA were conducted in the additional cell lines ZR75-30, MDAMB-453 and HCC-1428. A non-targeting control (NTC) siRNA that does not show significant homology to any sequence in the human genome was used as a negative control in all RNAi experiments (as described in technical notes at www.dharmacon.com). After 48 hours or 72 hours incubation at 37 C, cells were fixed in 3.7% formaldehyde and permeabilized in 0.1% Triton X-100, followed by labeling with a 1:500 dilution of anti-phospho histone H3 (pH3, Upstate) and subsequent 1:250 dilution of Alexa-fluor 488 (Molecular probes) Goat anti-rabbit secondary antibody. Cells were counterstained with Hoechst-33258 to allow identification of nuclei and the percentage of cells positive for nuclear pH3 immunofluorescence, also known as the Mitotic Index (30), was then quantitated for at least 1000 cells per well using Cellomics Target Activation software. All experiments were repeated at least three times. qRT-PCR (5'primer GATTCCAGCCGCTTCAGTT (SEQ ID NO: 5), 3' primer CCTGGCTGTGCTCTACACCT (SEQ ID NO: 6) on a ABI 7900 was performed to confirm that the siRNA pool resulted in 90% knockdown of ABCC3 relative to a control siRNA.

[0139] For ABCC3 overexpression experiments a full length ABCC3 cDNA cloned in the CMV promoter containing

vector pCMV5 (Invitrogen, Carlsbad, CA) was verified by sequencing the entire coding sequence. The construct was transfected into EVSA-T cells and stable clones were selected by growth in 1mg/ml geneticin (Invitrogen Carlsbad, CA). Overexpression of ABCC3 in stable clones was confirmed by qRT-PCR on cDNA derived from lines containing pCMV5-ABCC3, pCMV5 vector alone, or the parental EVSA-T strain. All stable cell lines described in this report were determined in qRT-PCR experiments to express at least 25-35X more ABCC3 transcript than vector control lines or the parental cell line.

Example 2 - Molecular characterization of cell lines

[0140] Affymetrix gene expression profiling was performed on cDNA prepared from total mRNA and Affymetrix 100K SNP array profiling was done on DNA from 44 breast cancer cell lines. Unsupervised analysis with the 11,000 most differentially expressed genes across the cell line panel was used to classify the cell lines into luminal and basal-like subtypes based on gene expression (Figure 11). Cell lines classified as luminal expressed high levels of estrogen receptor alpha (ER) and many of the target genes regulated by ER, including GATA3, HNF3A, IGF1R and XBP1. Cell lines classified as basal-like expressed high levels of some or all of the well described basal markers vimentin, caveolin, MFGE8 and the basal cytokeratins such as KRT5 (31). Because amplification of the HER2 oncogene clearly defines a separate disease subtype that is not apparent from overall gene expression classification in cell lines (14), the HER2 copy number was determined by qRT-PCR on genomic DNA and normalization to Line-1 repetitive elements for all cell lines (Figure 11). Cell lines that show apparent copy number greater than four in these analyses are indicated as HER2 amplified in the Table shown in Figure 11. The composite molecular subtype in Figure 11 is a classification derived from both the overall gene expression results as well as the HER2 copy number analysis. These findings agree with previous reports (14) and suggest that this collection of breast cancer cell lines reflects to some degree the major transcriptional distinctions that define breast cancer subtypes and to some extent are representative as models of subtypes as luminal, basal-like, and HER2 amplified tumors. Genome wide patterns of copy number gain and loss in the cell line panel show that the breast cancer cell lines harbor most of the major copy number alterations (e.g. MYC, CCND1, HER2 gain and p16, PTEN loss) that have been described in tumors. Subtype specific differences have been described (32). A finding relevant to this study is that amplification at 17q21.3 is common in HER2 amplified and luminal cell lines but not in basal-like cell lines.

Example 3 - In vitro sensitivity to anti-mitotic drugs

[0141] 31 breast cancer cell lines were screened for in vitro sensitivity to paclitaxel and MMAE. Figure 11 shows the IC50 value for each compound, defined as the concentration required for 50% inhibition of cell viability in a standard luciferin based viability assay in all of the cell lines. Notably there was significant correlation between the relative sensitivity to each agent across the panel of cell lines (Spearman rank order correlation coefficient, $r_s = 0.55$). In addition, Figure 1 shows that cell lines with the basal-like gene expression signature had lower average IC50 values and were more sensitive to each agent than luminal or HER2 amplified cell lines as determined by Kruskal-Wallis rank sum test (P-value = 0.002 for MMAE, P-value = 0.005 for paclitaxel)

Example 4 - Identification of Genomic Alterations that Correlate with in vitro sensitivity

[0142] The regions of chromosomal gain or loss that correlated with sensitivity to paclitaxel or MMAE were identified through supervised analysis of SNP array copy number data. First, cell lines were classified into either sensitive ($IC_{50} < 10nM$) or resistant (MMAE $IC_{50} > 100nM$, Paclitaxel $IC_{50} > 1000nM$) groups based on the sensitivity data. Then the maxT algorithm (26) was used to analyze data from approximately 115,000 SNPs and individual SNPs were identified where the mean copy number differed between sensitive and resistant classes with genome-wide significance. In the case of paclitaxel a group of SNPs on chromosome 17 starting at chromosome position 44,303,217 and ending at position 44,724,301 (17q21.21 to 17q21.23) showed statistically significant copy number differences between sensitive and resistant classes (P-value for rs2411377 = 0.04). The same group of markers also showed significant association between copy number and MMAE sensitivity (P-value for rs2411377 = 0.05). Figure 2a shows the relationship between paclitaxel sensitivity and genomic DNA copy number in this part of chromosome 17. A significant number of cell lines (8 out of 14) that showed resistance to paclitaxel had an increase in gene amplification within the region (as indicated by a diamond). The heatmap generated by the analysis showed a genomic DNA copy number of least four in this region. None of the cell lines showing sensitivity to paclitaxel had a significant increase in genomic DNA copy number in this region. Figure 2b shows similar data for MMAE sensitivity.

Example 5 - Identification of candidate genes in the interval

[0143] The chromosomal region from 17q21.31 to 17q21.33 encodes approximately 100 expressed transcripts according to the UC Santa Cruz Genome Browser (<http://genome.ucsc.edu>). Based on the principle that functionally relevant genes in regions of amplification should exhibit a concomitant increase in mRNA expression, this list was filtered down to 24 genes that showed significant overexpression upon amplification: ABCC3, COL1A1, CROP, EAP, EPN3, FLJ13855, FLJ20920, HOXB7, LOC201191, ITGB3, KIAA0924, KPNB1, LOC400604, LOC81558, MGC11242, MGC15396, NDP52, PDK2, PHB, PP1R9B, SLC35B1, SPOP, TOB1, WNT3. An example of significantly higher expression of the candidate gene ABCC3 (using Affymetrix expression probe set 208161_s_) in amplified cell lines compared to non-amplified cell lines is shown in Figure 3. The 24 genes were subjected to functional analysis to identify the locus responsible for conferring resistance to taxanes and auristatins.

Example 6 - Functional validation of ABCC3 by RNA interference

[0144] An RNA interference strategy was used to identify the gene responsible for mediating resistance to taxanes and auristatins in amplified cell lines. The assay employed made use of the fact that treatment of cells with paclitaxel or MMAE results in a block of cell cycle progression at M-phase that can be assayed by the presence of the mitotic marker phosphorylated histone H3 (33). Phosphorylation at Ser10 of histone H3 is tightly correlated with chromosome condensation during M phase, and the percentage of cells that are positive for pH3 staining, or mitotic index, can be determined through an immunofluorescence assay. Cellular knockdown of the gene mediating resistance should increase sensitivity of cell lines harboring the amplification to paclitaxel and MMAE and hence result in an accumulation of arrested cells and a higher mitotic index relative to control treated cells at a given drug concentration. Higher mitotic index correlates with reduction in viability and proliferation determined by other assays (COB and MRL, unpublished observations) but is a more specific readout of the anti-mitotic effects of these drugs. RNAi of 23 of the 24 candidate genes did not reproducibly result in accumulation of arrested cells and increased mitotic index in EFM-192A cells, but RNAi of ABCC3 resulted in a two to three fold increase in mitotic index relative to control treatment with a non-targeting control siRNA in the cell lines EFM-192A and ZR75-30 (Figure 4a-b). In contrast, ABCC3 RNAi did not appreciably alter the mitotic index in non-amplified cell lines HCC-1428 and MDA-MB-453 (Figure 4c-d). Similar results were obtained with MMAE.

Example 7 - Overexpression of ABCC3 causes in vitro multidrug resistance

[0145] EVSA-T cells were selected as a model to generate ABCC3-overexpressing lines, since they do not show ABCC3 amplification and express low levels of ABCC3 transcripts. Three independently derived lines were confirmed to overexpress ABCC3 transcripts and screened for in vitro sensitivity to paclitaxel and MMAE using an ATP-based luminescence assay. In this experiment, treatment of ABCC3 overexpressing clones did not result in 50% reduction of cell viability in a three day assay so the fold-change in sensitivity was assessed by calculating the concentration that resulted in half-maximal response, or EC50. The EC50 for the vector control treated with paclitaxel was 0.2 nM while the EC50 values for the ABCC3-expressing lines were 5 nM, 10 nM, and 80 nM, respectively. The EC50 for the vector control treated with MMAE was 0.05 nM while the EC50 values for the ABCC3-expressing lines were 1.5 nM, 12 nM, and 90nM, respectively.

[0146] All three overexpressing cell lines were at least 20-fold less sensitive to paclitaxel and MMAE based on EC50 values and also showed markedly less inhibition of cell growth compared to a vector-alone control stable cell line in an ATP-based luminescence assay (Figure 5).

Example 8 - Amplification of ABCC3 occurs in breast tumors

[0147] Analysis of the region of chromosome 17 encompassing HER2 and ABCC3 in the cell line 100K SNP array data suggested that the ABCC3 amplicon was most commonly associated with the HER2 amplified subtypes and was not seen in the cell lines classified as luminal or basal-like.

[0148] To ensure that ABCC3 amplification was not a cell line specific phenomenon, copy number data at the ABCC3 locus was characterized using Agilent Array CGH (aCGH) arrays on DNA from 145 primary breast tumors. These tumor samples were also classified into luminal, basal-like, and HER2 subtypes using a predictor based on expression levels of ER, PR and HER2 as described in (32). ABCC3 copy number gains (>3.5 copies) are present in 25% of HER2 amplified and 11% of luminal tumors but were not present in basal-like tumors.

Example 9 - FISH assay

[0149] To confirm the cytogenetic basis of the apparent copy number gains observed by SNP and aCGH arrays, a

fluorescence in situ hybridization (FISH) assay was developed using a BAC clone (see Example 1) spanning the ABCC3 locus and FISH analysis was performed on select cell lines and 61 primary tumors that had been classified as over-expressing HER2 based on the HerceptTest (IHC assay, reviewed in (35)). The FISH results from cell lines corroborated the data obtained from the SNP array and qPCR analyses. The breast cancer cell line EFM-192A predicted from SNP arrays to have elevated ABCC3 copy number did indeed exhibit a high level amplification of ABCC3 which is manifested as homogeneously staining regions (HSRs) with single or multiple integration into various chromosomes while maintaining single copies of HER2 and ABCC3 on chromosome 17. Cell lines predicted to be diploid for ABCC3 based on SNP array analysis were confirmed to be diploid based on FISH analysis with CEP 17 and ABCC3. FISH analysis of the 61 HER2 positive primary tumors that were screened for ABCC3 amplification confirmed that elevated copy number at ABCC3 is common in HER2 positive breast tumors. High level gene amplification (>2.2 ratio of ABCC3/CEP17) was seen in 25% of the tumors, while an additional 11% of the tumors showed moderate increases for ABCC3 (3-7 copies of ABCC3). Interestingly, a number of tumors show evidence of heterogeneity and exhibit cells with both very high level amplification of ABCC3 alongside cells with diploid copy number of ABCC3.

Example 10 - Overexpression of ABCC3 causes resistance to DM1

[0150] EVSA-T cells were stably transfected with an ABCC3 containing plasmid where ABCC3 is expressed at high levels from a cytomegalovirus (CMV) promoter. Overexpression of ABCC3 was confirmed by qRT-PCR. Three overexpressing clones and a control cell line were then analyzed for sensitivity to free DM1 in a standard cell viability assay and it was found that the overexpressing clones were more resistant to DM1 than the control cell line, consistent with ABCC3 overexpression leading to resistance to this agent (Figure 7).

Example 11- ABCC3 RNAi Enhances Response to MMAF antibody conjugate

[0151] EFM192A cells were transfected with ABCC3 siRNA and were subjected to treatment with trastuzumab (Herceptin) conjugated via the drug linker reagent maleimidocaproyl-valine-citrulline-PAB to MMAF (trastuzumab -mc-vc-PAB-MMAF). The EFM-192A cells transfected with ABCC3 siRNA are more sensitive to trastuzumab -mc-vc-PAB-MMAF than cells transfected with a control siRNA indicating that ABCC3 expression levels can impact sensitivity to this agent (Figure 8).

Example 12- ABCC3 RNAi Enhances Response to Free DM1 and Trastuzumab-smcc-DM1 Conjugate

[0152] EFM-192A cells transfected with ABCC3 siRNA are more sensitive to either free DM1 or Trastuzumab-smcc-DM1 conjugate than cells transfected with a control siRNA (NTC), indicating that ABCC3 expression levels can impact sensitivity to these agents (Figure 9a and 9b).

Example 13 - ABCC3 amplification status correlates with T-DM1 activity

[0153] ABCC3 FISH analysis was performed on samples obtained from the T-DM1 Phase II (TDM4258G) trial to explore the effect of ABCC3 amplification on T-DM1 activity in HER2 amplified breast tumors. The TDM4258G trial is a multi-institutional, open-label, single-arm, Phase II study of T-DM1 administered by IV infusion to patients with HER2-positive metastatic breast cancer. The patients in the trial had shown prior progression on HER2-directed therapy. Formalin Fixed Paraffin Embedded (FFPE) archival tumor tissue samples from the clinical trial was obtained from the clinical investigation sites with appropriate IRB approval and patient consent.

[0154] The FISH assay was performed on the clinical trial samples as described in Example 1. Figure 10 shows the data from the analysis of the FISH assay sorted by ratio of ABCC3/CEP17. Those samples with ABCC3/CEP17 ratios of 1.8 and above are considered to have ABCC3 amplification. 80% (12/15) of patients whose samples showed no amplification of ABCC3 responded to treatment to T-DM1 while 40% (2/5) of patients whose samples showed amplification of ABCC3 responded to T-DM1 treatment. This analysis indicates that ABCC3 amplification status is useful in determining the likely response of a patient to treatment with T-DM1.

References

[0155]

1. O'Driscoll L, Clynes M. Biomarkers and multiple drug resistance in breast cancer. *Curr Cancer Drug Targets* 2006;6(5):365-84.
2. Cigler T, Goss PE. Breast cancer adjuvant endocrine therapy. *Cancer journal* (Sudbury, Mass 2007;13(3):148-55.

3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 2001;344(11):783-92.
4. Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. *Eur J Nucl Med Mol Imaging* 2004;31 Suppl 1:5149-61.
5. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. *Nature reviews* 2006;5(3):219-34.
6. Katsnelson A. Cautious welcome for FDA pharmacogenomics guidance. *Nat Biotechnol* 2005;23(5):510.
7. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. *Proc Natl Acad Sci U S A* 2007;104(32):13086-91.
10. Szakacs G, Annereau JP, Lababidi S, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. *Cancer Cell* 2004;6(2):129-37.
9. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci U S A* 2003;100(14):8418-23.
10. Finnegan TJ, Carey LA. Gene-expression analysis and the basal-like breast cancer subtype. *Future Oncol* 2007;3(1):55-63.
11. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. *BMC Genomics* 2006;7:96.
12. Kurt M, Harputluoglu H, Dede DS, Gullu IH, Altundag K. Potential molecular targeted therapies in the management of the basal-like subtype of breast cancer. *Breast* 2007;16(2):111-2.
13. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. *Clin Cancer Res* 2005;11(16):5678-85.
14. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell* 2006; 10(6):515-27.
15. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. *Nat Biotechnol* 2003;21(7):778-84.
16. Crown J, O'Leary M. The taxanes: an update. *Lancet* 2000;355(9210):1176-8.
17. Zhao X, Li C, Paez JG, et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. *Cancer Res* 2004;64(9):3060-71.
18. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. *Nature* 2005;436(7047):117-22.
19. Gorringe KL, Chin SF, Pharoah P, et al. Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer. *Carcinogenesis* 2005;26(5):923-30.
20. Rae JM, Ramus SJ, Waltham M, et al. Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. *Clin Exp Metastasis* 2004;21(6):543-52.
21. Barrett MT, Scheffer A, Ben-Dor A, et al. Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. *Proc Natl Acad Sci USA* 2004;101(51):17765-70.
22. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. *Proc Natl Acad Sci U S A* 1998;95(25):14863-8.
23. Matsuzaki H, Dong S, Loi H, et al. Genotyping over 100,000 SNPs on a pair of oligonucleotide arrays. *Nat Methods* 2004;1(2):109-11.
24. Hupe P, Stransky N, Thiery JP, Radvanyi F, Barillot E. Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. *Bioinformatics* 2004;20(18):3413-22.
25. Beroukhir R, Getz G, Nghiemphu L, et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. *Proc Natl Acad Sci U S A* 2007;104(50):20007-12.
26. Westphal P, Young S. Resampling-based multiple testing: Examples and methods for p-value adjustment. : John Wiley & Sons 1993.
27. Fanning TG, Singer MF. LINE-1: a mammalian transposable element. *Biochimica et biophysica acta* 1987;910(3):203-12.
28. Kindich R, Flori AR, Jung V, et al. Application of a modified real-time PCR technique for relative gene copy number quantification to the determination of the relationship between NKX3.1 loss and MYC gain in prostate cancer. *Clin Chem* 2005;51(3):649-52.
29. Bayani J, Zielenska M, Marrano P, et al. Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. *J Neurosurg* 2000;93(3):437-48.
30. Grove LE, Ghosh RN. Quantitative characterization of mitosis-blocked tetraploid cells using high content analysis. *Assay and drug development technologies* 2006;4(4):421-42.
31. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. *Mod Pathol* 2006;19(2):264-71.

32. Hu X SH, O'Brien C, Honchell, Wu T, Chant J, Lackner M, Cavet G. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. *Molecular Cancer Research*, in press (April, 2009).
33. Gasparri F, Cappella P, Galvani A. Multiparametric cell cycle analysis by automated microscopy. *J Biomol Screen* 2006;11(6):586-98.
- 5 34. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. *J Natl Cancer Inst* 2000;92(16):1295-302.
35. Carlsson J, Nordgren H, Sjostrom J, et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. *Br J Cancer* 2004;90(12):2344-8.
36. Liu Y, Peng H, Zhang JT. Expression profiling of ABC transporters in a drug-resistant breast cancer cell line using AmpArray. *Mol Pharmacol* 2005;68(2):430-8.
- 10 37. Huang R, Murry DJ, Kolwankar D, Hall SD, Foster DR. Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. *Biochem Pharmacol* 2006;71(12):1695-704.
38. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. *Int J Cancer* 2005;116(5):824-9.
- 15 39. Hopper-Borge E, Chen ZS, Shchavezleva I, Belinsky MG, Kruh GD. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. *Cancer Res* 2004;64(14):4927-30.
40. Lagas JS, Vlaming ML, van Tellingen O, et al. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. *Clin Cancer Res* 2006; 12(20 Pt 1):6125-32.
41. Kool M, van der Linden M, de Haas M, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. *Proc Natl Acad Sci U S A* 1999;96(12):6914-9.
- 20 42. Zeng H, Bain LJ, Belinsky MG, Kruh GD. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. *Cancer Res* 1999;59(23):5964-7.
43. Mahjoubi F, Hill RJ, Peters GB. Chromosome microdissection identifies genomic amplifications associated with drug resistance in a leukemia cell line: an approach to understanding drug resistance in cancer. *Chromosome Res* 2006;14(3):263-76.
- 25 44. Schmidt M, Bremer E, Hasenclever D, et al. Role of the progesterone receptor for paclitaxel resistance in primary breast cancer. *Br J Cancer* 2007;96(2):241-7.
45. Shajahan AN, Wang A, Decker M, Minshall RD, Liu MC, Clarke R. Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. *J Biol Chem* 2006.
- 30 46. Pinilla SM, Honrado E, Hardisson D, Benitez J, Palacios J. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. *Breast Cancer Res Treat* 2006;99(1):85-90.
47. Savage K, Lambros MB, Robertson D, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. *Clin Cancer Res* 2007;13(1):90-101.
- 35 48. Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. *Proc Natl Acad Sci U S A* 2005; 102(23):8315-20.
49. Wagner P, Wang B, Clark E, Lee H, Rouzier R, Puszta L. Microtubule Associated Protein (MAP)-Tau: a novel mediator of Paclitaxel sensitivity in vitro and in vivo. *Cell Cycle* 2005;4(9):1149-52.
- 40 50. Lambros MB, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. *Hum Pathol* 2007;38(8):1105-22.
51. Hann CL, Brahmer JR. "Who shouted receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?" *Curr Treat Options Oncol* 2007;8(1):28-37.
- 45 52. Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. *N Engl J Med* 2007;357(15):1496-506.

[0156] Although the invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, the descriptions and examples should not be construed as limiting the scope of the invention.

Claims

1. A method for determining whether a breast cancer in a patient is resistant to treatment with an anti-mitotic agent-antibody conjugate comprising an anti-mitotic agent selected from an auristatin and a maytansinoid covalently linked to an antibody, said method comprising detecting whether the ABCC3 gene is amplified or overexpressed in a test breast cancer sample from the patient, wherein amplification or overexpression of the ABCC3 gene indicates that the breast cancer is resistant to treatment with the anti-mitotic agent-antibody conjugate.

2. The method of claim 1 comprising detecting whether the ABCC3 gene is amplified, wherein detecting the amplification of the ABCC3 gene comprises determining the copy number of the ABCC3 gene, wherein a copy number of at least 3 indicates ABCC3 gene amplification.
- 5 3. The method of claim 2, wherein a copy number of at least 5 indicates ABCC3 gene amplification.
4. The method of claim 1 comprising detecting whether the ABCC3 gene is overexpressed wherein detecting overexpression of the ABCC3 gene comprises determining the level of mRNA transcription from the ABCC3 gene.
- 10 5. The method of claim 4 wherein overexpression of the ABCC3 gene is indicated by an at least 5-fold increase in mRNA transcription level from the ABCC3 gene in the test cancer sample relative to a control sample.
6. The method of claim 5 wherein overexpression of the ABCC3 gene is indicated by an at least 25-fold increase in mRNA transcription level from the ABCC3 gene in the test cancer sample relative to a control sample.
- 15 7. The method of claim 1 comprising detecting whether the ABCC3 gene is overexpressed wherein detecting overexpression of the ABCC3 gene comprises determining the level of ABCC3 polypeptide expression.
8. The method of claim 7 wherein determining the level of ABCC3 polypeptide expression comprises contacting the test breast cancer sample with an anti-ABCC3 antibody and detecting binding of the anti-ABCC3 antibody to ABCC3 polypeptide.
- 20 9. The method of claim 7 wherein overexpression of the ABCC3 gene is indicated by an at least 2-fold increase in the level of expression of ABCC3 polypeptide in the test breast cancer sample relative to a control sample.
- 25 10. The method of claim 7 wherein overexpression of the ABCC3 gene is indicated by an at least 10-fold increase in the level of expression of ABCC3 polypeptide in the test breast cancer sample relative to a control sample.
- 30 11. The method of claim 2 or 3, wherein the copy number of the ABCC3 gene is determined by fluorescence in situ hybridization (FISH), Southern Blot, immunohistochemistry (IHC), polymerase chain reaction (PCR), quantitative PCR (qPCR), quantitative real-time PCR (qRT-PCR), comparative genomic hybridization, microarray based comparative genomic hybridization, or ligase chain reaction (LCR).
- 35 12. The method of claim 1, wherein the breast cancer is Her2 positive breast cancer.
13. The method of claim 1, wherein the anti-mitotic agent is:
 - (a) an auristatin selected from the group consisting of monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF); or
 - 40 (b) a maytansinoid selected from the group consisting of DM1 and DM4.
14. The method of claim 1 or claim 13, wherein the anti-mitotic agent- antibody conjugate is a maytansinoid- anti-Her2 antibody conjugate.
- 45 15. The method of claim 14, wherein the maytansinoid- anti-Her2 antibody conjugate is trastuzumab-DM1.
16. An anti-mitotic agent-antibody conjugate comprising an anti-mitotic agent selected from an auristatin and a maytansinoid covalently linked to an antibody, for use in a method of treating a patient with a breast cancer that is resistant to the anti-mitotic agent-antibody conjugate, the method comprising administering to the patient an antagonist of ABCC3 and the anti-mitotic agent-antibody conjugate, wherein the patient's breast cancer has been determined as resistant to the anti-mitotic agent-antibody conjugate by detecting that ABCC3 gene is amplified or overexpressed in a test breast cancer sample of the patient.
- 50 17. An antagonist of ABCC3 for use in a method of treating a patient with a breast cancer that is resistant to an anti-mitotic agent-antibody conjugate comprising an anti-mitotic agent selected from an auristatin and a maytansinoid covalently linked to an antibody, the method comprising administering to the patient the antagonist of ABCC3 and the anti-mitotic agent-antibody conjugate, wherein the patient's cancer has been determined as resistant to the anti-mitotic agent-antibody conjugate by detecting that ABCC3 gene is amplified or overexpressed in a test breast cancer

sample of the patient.

18. The anti-mitotic agent-antibody conjugate for use according to claim 16 or the antagonist of ABCC3 for use according to claim 17, wherein the antagonist is selected from the group consisting of an ABCC3 antibody and an siRNA that binds to ABCC3.
19. The anti-mitotic agent-antibody conjugate for use according to claim 16 or antagonist of ABCC3 for use according to claim 17, wherein the breast cancer is Her2 positive breast cancer.
20. An anti-mitotic agent-antibody conjugate comprising an anti-mitotic agent selected from an auristatin and a maytansinoid covalently linked to an antibody for use in a method of treating breast cancer, the method comprising
 - a) selecting a patient based on absence of ABCC3 amplification or overexpression in the patient's cancer, and
 - b) administering to the patient a therapeutically effective amount of the anti-mitotic agent-antibody conjugate.
21. The anti-mitotic agent-antibody conjugate for use according to claim 20, wherein the selected patient has Her2 positive breast cancer.
22. The anti-mitotic agent-antibody conjugate for use according to claim 20 or claim 21, wherein the anti-mitotic agent is an anti-Her2 antibody-anti-mitotic agent conjugate.
23. The anti-mitotic agent-antibody conjugate for use according to claim 22, wherein the anti-Her2 antibody-anti-mitotic agent conjugate is trastuzumab-DM1 or trastuzumab-MMAE.
24. The method of claim 1 for determining whether a breast cancer in a patient is resistant to treatment with an anti-mitotic agent-antibody conjugate, said anti-mitotic agent-antibody conjugate comprising an anti-mitotic agent selected from an auristatin and a maytansinoid covalently linked to trastuzumab.
25. The anti-mitotic agent-antibody conjugate for use according to claim 16, comprising an anti-mitotic agent selected from an auristatin and a maytansinoid covalently linked to trastuzumab.
26. The antagonist of ABCC3 for use according to claim 17, said anti-mitotic agent-antibody conjugate comprising an anti-mitotic agent selected from an auristatin and a maytansinoid covalently linked to trastuzumab.
27. The anti-mitotic agent-antibody conjugate for use according to claim 20, said anti-mitotic agent-antibody conjugate comprising an anti-mitotic agent selected from an auristatin and a maytansinoid covalently linked to trastuzumab.
28. The method of claim 1 for determining whether a breast cancer in a patient is resistant to treatment with an anti-mitotic agent-antibody conjugate, said anti-mitotic agent-antibody conjugate comprising an anti-mitotic agent selected from monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), DM1, and DM4.
29. The anti-mitotic agent-antibody conjugate for use according to claim 16, comprising an anti-mitotic agent selected from monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), DM1, and DM4.
30. The antagonist of ABCC3 for use according to claim 17, said anti-mitotic agent-antibody conjugate comprising an anti-mitotic agent selected from monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), DM1, and DM4.
31. The anti-mitotic agent-antibody conjugate for use according to claim 20, said anti-mitotic agent-antibody conjugate comprising an anti-mitotic agent selected from monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), DM1, and DM4.

Patentansprüche

1. Verfahren zum Bestimmen, ob ein Brustkrebs bei einem Patienten resistent ist gegen eine Behandlung mit einem Antimitose-Mittel-Antikörper-Konjugat, das ein aus einem Auristatin und einem Maytansinoid ausgewähltes Antimitose-Mittel, das kovalent mit einem Antikörper verbunden ist, umfasst, wobei das Verfahren das Detektieren umfasst, ob das ABCC3-Gen in einer Test-Brustkrebsprobe von dem Patienten amplifiziert oder überexprimiert ist, wobei

eine Amplifikation oder Überexpression des ABCC3-Gens darauf hinweist, dass der Brustkrebs gegen eine Behandlung mit dem Antimitose-Mittel-Antikörper-Konjugat resistent ist.

2. Verfahren nach Anspruch 1, das das Detektieren, ob das ABCC3-Gen amplifiziert ist, umfasst, wobei das Detektieren der Amplifikation des ABCC3-Gens das Bestimmen der Kopienzahl des ABCC3-Gens umfasst, wobei eine Kopienzahl von zumindest 3 auf eine ABCC3-Genamplifikation hinweist.
3. Verfahren nach Anspruch 2, wobei eine Kopienzahl von zumindest 5 auf eine ABCC3-Genamplifikation hinweist.
4. Verfahren nach Anspruch 1, das das Detektieren umfasst, ob das ABCC3-Gen überexprimiert ist, wobei das Detektieren einer Überexpression des ABCC3-Gens das Bestimmen des mRNA-Transkriptionsausmaßes des ABCC3-Gens umfasst.
5. Verfahren nach Anspruch 4, wobei eine Überexpression des ABCC3-Gens durch einen zumindest 5fachen Anstieg des mRNA-Transkriptionsausmaßes des ABCC3-Gens in der Testkrebsprobe im Vergleich mit einer Kontrollprobe angezeigt wird.
6. Verfahren nach Anspruch 5, wobei eine Überexpression des ABCC3-Gens durch einen zumindest 25fachen Anstieg des mRNA-Transkriptionsausmaßes des ABCC3-Gens in der Testkrebsprobe im Vergleich mit einer Kontrollprobe angezeigt wird.
7. Verfahren nach Anspruch 1, das das Detektieren umfasst, ob das ABCC3-Gen überexprimiert ist, wobei das Detektieren einer Überexpression des ABCC3-Gens das Bestimmen des ABCC3-Polypeptidexpressionsausmaßes umfasst.
8. Verfahren nach Anspruch 7, wobei das Bestimmen des ABCC3-Polypeptidexpressionsausmaßes das Kontaktieren der Testbrustkrebsprobe mit einem Anti-ABCC3-Antikörper und das Detektieren der Bindung des Anti-ABCC3-Antikörpers an das ABCC3-Polypeptid umfasst.
9. Verfahren nach Anspruch 7, wobei eine Überexpression des ABCC3-Gens durch einen zumindest 2fachen Anstieg des Expressionsausmaßes des ABCC3-Polypeptids in der Testbrustkrebsprobe im Vergleich zu einer Kontrollprobe angezeigt wird.
10. Verfahren nach Anspruch 7, wobei eine Überexpression des ABCC3-Gens durch einen zumindest 10fachen Anstieg des Expressionsausmaßes des ABCC3-Polypeptids in der Testbrustkrebsprobe im Vergleich zu einer Kontrollprobe angezeigt wird.
11. Verfahren nach Anspruch 2 oder 3, wobei die Kopienzahl des ABCC3-Gens durch Fluoreszenz-in-situ-Hybridisierung (FISH), Southern-Blot, Immunhistochemie (IHC), Polymerase-Kettenreaktion (PCR), quantitative PCR (qPCR), quantitative Echtzeit-PCR (qRT-PCR), komparative genomische Hybridisierung, Microarray-basierte komparative genomische Hybridisierung oder Ligase-Kettenreaktion (LCR) bestimmt wird.
12. Verfahren nach Anspruch 1, wobei der Brustkrebs ein Her2-positiver Brustkrebs ist.
13. Verfahren nach Anspruch 1, wobei das Antimitose-Mittel:
 - (a) ein Auristatin, ausgewählt aus der Gruppe bestehend aus Monomethylauristatin E (MMAE) und Monomethylauristatin F (MMAF), ist; oder
 - (b) ein Maytansinoid, ausgewählt aus der Gruppe bestehend aus DM1 und DM4, ist.
14. Verfahren nach Anspruch 1 oder 13, wobei das Antimitose-Mittel-Antikörper-Konjugat ein Maytansinoid-Anti-Her2-Antikörper-Konjugat ist.
15. Verfahren nach Anspruch 14, wobei das Maytansinoid-Anti-Her2-Antikörper-Konjugat Trastuzumab-DM1 ist.
16. Antimitose-Mittel-Antikörper-Konjugat, das ein aus einem Auristatin und einem Maytansinoid ausgewähltes Antimitose-Mittel kovalent an einen Antikörper gebunden umfasst, zur Verwendung in einem Verfahren zur Behandlung eines Patienten mit einem Brustkrebs, der gegen das Antimitose-Mittel-Antikörper-Konjugat resistent ist, wobei das

Verfahren das Verabreichen eines Antagonisten von ABCC3 und des Antimitose-Mittel-Antikörper-Konjugats an den Patienten umfasst, wobei der Brustkrebs des Patienten als gegen das Antimitose-Mittel-Antikörper-Konjugat resistent bestimmt wurde, indem detektiert wurde, dass das ABCC3-Gen in einer Testbrustkrebsprobe des Patienten amplifiziert oder überexprimiert ist.

- 5
 - 10
 - 15
 - 20
 - 25
 - 30
 - 35
 - 40
 - 45
 - 50
 - 55
17. Antagonist von ABCC3 zur Verwendung in einem Verfahren zum Behandeln eines Patienten mit einem Brustkrebs, der gegen ein Antimitose-Mittel-Antikörper-Konjugat resistent ist, das ein aus einem Auristatin und einem Maytansinoid ausgewähltes Antimitose-Mittel kovalent an einen Antikörper gebunden umfasst, wobei das Verfahren das Verabreichen des Antagonisten von ABCC3 und des Antimitose-Mittel-Antikörper-Konjugats an den Patienten umfasst, wobei der Krebs des Patienten als gegen das Antimitose-Mittel-Antikörper-Konjugat resistent bestimmt wurde, indem detektiert wurde, dass das ABCC3-Gen in einer Testbrustkrebsprobe des Patienten amplifiziert oder überexprimiert ist.
 18. Antimitose-Mittel-Antikörper-Konjugat zur Verwendung nach Anspruch 16 oder Antagonist von ABCC3 zur Verwendung nach Anspruch 17, wobei der Antagonist aus der Gruppe bestehend aus einem ABCC3-Antikörper und einer siRNA, die an ABCC3 bindet, ausgewählt ist.
 19. Antimitose-Mittel-Antikörper-Konjugat zur Verwendung nach Anspruch 16 oder Antagonist von ABCC3 zur Verwendung nach Anspruch 17, wobei der Brustkrebs ein Her2-positiver Brustkrebs ist.
 20. Antimitose-Mittel-Antikörper-Konjugat, das ein aus einem Auristatin und einem Maytansinoid ausgewähltes Antimitose-Mittel kovalent an einen Antikörper gebunden umfasst, zur Verwendung in einem Verfahren zur Behandlung von Brustkrebs, wobei das Verfahren umfasst:
 - a) das Auswählen eines Patienten basierend auf der Abwesenheit einer ABCC3-Amplifikation oder -Überexpression im Krebs des Patienten und
 - b) das Verabreichen von einer therapeutisch wirksamen Menge des Antimitose-Mittel-Antikörper-Konjugats an den Patienten.
 21. Antimitose-Mittel-Antikörper-Konjugat zur Verwendung nach Anspruch 20, wobei der ausgewählte Patient einen Her2-positiven Brustkrebs hat.
 22. Antimitose-Mittel-Antikörper-Konjugat zur Verwendung nach Anspruch 20 oder Anspruch 21, wobei das Antimitose-Mittel ein Anti-Her-2-Antikörper-Antimitose-Mittel-Konjugat ist.
 23. Antimitose-Mittel-Antikörper-Konjugat zur Verwendung nach Anspruch 22, wobei das Anti-Her2-Antikörper-Antimitose-Mittel-Konjugat Trastuzumab-DM1 oder Trastuzumab-MMAE ist.
 24. Verfahren nach Anspruch 1 zum Bestimmen, ob ein Brustkrebs bei einem Patienten resistent ist gegen die Behandlung mit einem Antimitose-Mittel-Antikörper-Konjugat, wobei das Antimitose-Mittel-Antikörper-Konjugat ein aus einem Auristatin oder einem Maytansinoid ausgewähltes Antimitose-Mittel kovalent an Trastuzumab gebunden umfasst.
 25. Antimitose-Mittel-Antikörper-Konjugat zur Verwendung nach Anspruch 16, das ein aus einem Auristatin und einem Maytansinoid ausgewähltes Antimitose-Mittel kovalent an Trastuzumab gebunden umfasst.
 26. Antagonist von ABCC3 zur Verwendung nach Anspruch 17, wobei das Antimitose-Mittel-Antikörper-Konjugat ein aus einem Auristatin und einem Maytansinoid ausgewähltes Antimitose-Mittel kovalent an Trastuzumab gebunden umfasst.
 27. Antimitose-Mittel-Antikörper-Konjugat zur Verwendung nach Anspruch 20, wobei das Antimitose-Mittel-Antikörper-Konjugat ein aus einem Auristatin und einem Maytansinoid ausgewähltes Antimitose-Mittel kovalent an Trastuzumab gebunden umfasst.
 28. Verfahren nach Anspruch 1 zum Bestimmen, ob ein Brustkrebs bei einem Patienten resistent ist gegen die Behandlung mit einem Antimitose-Mittel-Antikörper-Konjugat, wobei das Antimitose-Mittel-Antikörper-Konjugat ein Antimitose-Mittel umfasst, das aus Monomethylauristatin E (MMAE), Monomethylauristatin F (MMAF), DM1 und DM4 ausgewählt ist.

29. Antimitose-Mittel-Antikörper-Konjugat zur Verwendung nach Anspruch 16, das ein Antimitose-Mittel umfasst, das aus Monomethylauristatin E (MMAE), Monomethylauristatin F (MMAF), DM1 und DM4 ausgewählt ist.

30. Antagonist von ABCC3 zur Verwendung nach Anspruch 17, wobei das Antimitose-Mittel-Antikörper-Konjugat ein Antimitose-Mittel umfasst, das aus Monomethylauristatin E (MMAE), Monomethylauristatin F (MMAF), DM1 und DM4 ausgewählt ist.

31. Antimitose-Mittel-Antikörper-Konjugat zur Verwendung nach Anspruch 20, wobei das Antimitose-Mittel-Antikörper-Konjugat ein Antimitose-Mittel umfasst, das aus Monomethylauristatin E (MMAE), Monomethylauristatin F (MMAF), DM1 und DM4 ausgewählt ist.

Revendications

1. Procédé permettant de déterminer si un cancer du sein chez un patient est résistant au traitement avec un conjugué agent antimitotique-anticorps comprenant un agent antimitotique choisi parmi une auristatine et un maytansinoïde lié de manière covalente à un anticorps, ledit procédé comprenant l'étape consistant à détecter si le gène ABCC3 est amplifié ou surexprimé dans un échantillon test du cancer du sein prélevé chez le patient, dans lequel l'amplification ou la surexpression du gène ABCC3 indique que le cancer du sein est résistant au traitement avec le conjugué agent antimitotique-anticorps.

2. Procédé selon la revendication 1, comprenant l'étape consistant à détecter si le gène ABCC3 est amplifié, dans lequel la détection de l'amplification du gène ABCC3 consiste à déterminer le nombre de copies du gène ABCC3, un nombre de copies d'au moins 3 indiquant l'amplification du gène ABCC3.

3. Procédé selon la revendication 2, dans lequel un nombre de copies d'au moins 5 indique l'amplification du gène ABCC3.

4. Procédé selon la revendication 1, comprenant l'étape consistant à détecter si le gène ABCC3 est surexprimé, dans lequel la détection de la surexpression du gène ABCC3 consiste à déterminer le taux de transcription de l'ARNm provenant du gène ABCC3.

5. Procédé selon la revendication 4, dans lequel la surexpression du gène ABCC3 est indiquée par une augmentation d'au moins un facteur 5 du taux de transcription de l'ARNm provenant du gène ABCC3 dans l'échantillon test de cancer par rapport à un échantillon témoin.

6. Procédé selon la revendication 5, dans lequel la surexpression du gène ABCC3 est indiquée par une augmentation d'au moins un facteur 25 du taux de transcription de l'ARNm provenant du gène ABCC3 dans l'échantillon test de cancer par rapport à un échantillon témoin.

7. Procédé selon la revendication 1, comprenant l'étape consistant à détecter si le gène ABCC3 est surexprimé, dans lequel la détection de la surexpression du gène ABCC3 consiste à déterminer le taux d'expression du polypeptide ABCC3.

8. Procédé selon la revendication 7, dans lequel la détermination du taux d'expression du polypeptide ABCC3 comprend la mise en contact de l'échantillon test de cancer du sein avec un anticorps anti-ABCC3 et la détection de la liaison de l'anticorps anti-ABCC3 au polypeptide ABCC3.

9. Procédé selon la revendication 7, dans lequel la surexpression du gène ABCC3 est indiquée par une augmentation d'au moins un facteur 2 du taux d'expression du polypeptide ABCC3 dans l'échantillon test de cancer du sein par rapport à un échantillon témoin.

10. Procédé selon la revendication 7, dans lequel la surexpression du gène ABCC3 est indiquée par une augmentation d'au moins un facteur 10 du taux d'expression du polypeptide ABCC3 dans l'échantillon test de cancer du sein par rapport à un échantillon témoin.

11. Procédé selon la revendication 2 ou 3, dans lequel le nombre de copies du gène ABCC3 est déterminé par hybridation in situ par fluorescence (FISH), méthode de Southern Blot, immunohistochimie (IHC), réaction en chaîne par poly-

mérase (PCR), PCR quantitative (qPCR), PCR quantitative en temps réel (qRT-PCR), hybridation génomique comparative, hybridation génomique comparative à base de micropuces, ou réaction en chaîne par ligase (LCR).

12. Procédé selon la revendication 1, dans lequel le cancer du sein est un cancer du sein Her2 positif.

13. Procédé selon la revendication 1, dans lequel l'agent antimitotique est :

(a) une auristatine choisie dans le groupe constitué par la monométhylauristatine E (MMAE) et la monométhylauristatine F (MMAF) ; ou

(b) un maytansinoïde choisi dans le groupe constitué par DM1 et DM4.

14. Procédé selon la revendication 1 ou la revendication 13, dans lequel le conjugué agent antimitotique-anticorps est un conjugué maytansinoïde-anticorps anti-Her2.

15. Procédé selon la revendication 14, dans lequel le conjugué maytansinoïde-anticorps anti-Her2 est le trastuzumab-DM1.

16. Conjugué agent antimitotique-anticorps comprenant un agent antimitotique choisi parmi une auristatine et un maytansinoïde lié de manière covalente à un anticorps, pour l'utilisation dans un procédé de traitement d'un patient atteint d'un cancer du sein qui est résistant au conjugué agent antimitotique-anticorps, le procédé comprenant l'étape consistant à administrer au patient un antagoniste de ABCC3 et le conjugué agent antimitotique-anticorps, dans lequel le cancer du sein du patient a été déterminé comme étant résistant au conjugué agent antimitotique-anticorps en détectant si le gène ABCC3 est amplifié ou surexprimé dans un échantillon test de cancer du sein du patient.

17. Antagoniste de ABCC3 pour l'utilisation dans un procédé de traitement d'un patient atteint d'un cancer du sein qui est résistant au conjugué agent antimitotique-anticorps comprenant un agent antimitotique choisi parmi une auristatine et un maytansinoïde lié de manière covalente à un anticorps, le procédé comprenant l'étape consistant à administrer au patient l'antagoniste de ABCC3 et le conjugué agent antimitotique-anticorps, dans lequel le cancer du patient a été déterminé comme étant résistant au conjugué agent antimitotique-anticorps en détectant si le gène ABCC3 est amplifié ou surexprimé dans un échantillon test de cancer du sein du patient.

18. Conjugué agent antimitotique-anticorps pour l'utilisation selon la revendication 16 ou antagoniste de ABCC3 pour l'utilisation selon la revendication 17, l'antagoniste étant choisi dans le groupe constitué par un anticorps de ABCC3 et un ARNsi qui se lie à ABCC3.

19. Conjugué agent antimitotique-anticorps pour l'utilisation selon la revendication 16 ou antagoniste de ABCC3 pour l'utilisation selon la revendication 17, le cancer du sein étant un cancer du sein Her2 positif.

20. Conjugué agent antimitotique-anticorps comprenant un agent antimitotique choisi parmi une auristatine et un maytansinoïde lié de manière covalente à un anticorps pour l'utilisation dans un procédé de traitement du cancer du sein, le procédé comprenant l'étape consistant à

a) sélectionner un patient sur la base de l'absence d'amplification ou de surexpression de ABCC3 dans le cancer du patient, et

b) administrer au patient une quantité thérapeutiquement efficace du conjugué agent antimitotique-anticorps.

21. Conjugué agent antimitotique-anticorps pour l'utilisation selon la revendication 20, le patient sélectionné ayant un cancer du sein Her2 positif.

22. Conjugué agent antimitotique-anticorps pour l'utilisation selon la revendication 20 ou la revendication 21, l'agent antimitotique étant un conjugué agent antimitotique-anticorps anti-Her2.

23. Conjugué agent antimitotique-anticorps pour l'utilisation selon la revendication 22, le conjugué agent antimitotique-anticorps anti-Her2 étant le trastuzumab-DM1 ou le trastuzumab-MMAE.

24. Procédé selon la revendication 1 permettant de déterminer si un cancer du sein chez un patient est résistant au traitement avec un conjugué agent antimitotique-anticorps, ledit conjugué agent antimitotique-anticorps comprenant

un agent antimitotique choisi parmi une auristatine et un maytansinoïde lié de manière covalente au trastuzumab.

25. Conjugué agent antimitotique-anticorps pour l'utilisation selon la revendication 16, comprenant un agent antimitotique choisi parmi une auristatine et un maytansinoïde lié de manière covalente au trastuzumab.

5

26. Antagoniste de ABCC3 pour l'utilisation selon la revendication 17, ledit conjugué agent antimitotique-anticorps comprenant un agent antimitotique choisi parmi une auristatine et un maytansinoïde lié de manière covalente au trastuzumab.

10

27. Conjugué agent antimitotique-anticorps pour l'utilisation selon la revendication 20, ledit conjugué agent antimitotique-anticorps comprenant un agent antimitotique choisi parmi une auristatine et un maytansinoïde lié de manière covalente au trastuzumab.

15

28. Procédé selon la revendication 1 permettant de déterminer si un cancer du sein chez un patient est résistant au traitement avec un conjugué agent antimitotique-anticorps, ledit conjugué agent antimitotique-anticorps comprenant un agent antimitotique choisi parmi la monométhylauristatine E (MMAE), la monométhylauristatine F (MMAF), le DM1 et le DM4.

20

29. Conjugué agent antimitotique-anticorps pour l'utilisation selon la revendication 16, comprenant un agent antimitotique choisi parmi la monométhylauristatine E (MMAE), la monométhylauristatine F (MMAF), le DM1 et le DM4.

25

30. Antagoniste de ABCC3 pour l'utilisation selon la revendication 17, ledit conjugué agent antimitotique-anticorps comprenant un agent antimitotique choisi parmi la monométhylauristatine E (MMAE), la monométhylauristatine F (MMAF), le DM1 et le DM4.

30

31. Conjugué agent antimitotique-anticorps pour l'utilisation selon la revendication 20, ledit conjugué agent antimitotique-anticorps comprenant un agent antimitotique choisi parmi la monométhylauristatine E (MMAE), la monométhylauristatine F (MMAF), le DM1 et le DM4.



35

40

45

50

55







FIG. 2A






FIG. 3




FIG. 4B




FIG. 4D




FIG. 4A







FIG. 4C






○ EFM192A
□ MDAMB361
◇ BT474
■ AU565
▲ EFM19
▼ MDAMB468

Cell Line	IC50 (nM)
EFM192A	>100
MDAMB361	>100
BT474	>100
AU565	0.36
EFM19	0.55
MDAMB468	0.53



FIG. 6A





○ EFM192A
□ MDAMB361
◇ BT474
■ AU565
▼ MDAMB468
▲ EFM19

Cell Line	IC50 (nM)
EFM192A	>1000
MDAMB361	>1000
BT474	>1000
AU565	11.60
MDAMB468	8.96
EFM19	3.23

FIG. 6B

**FIG. 7****FIG. 8**

**FIG. 9A****FIG. 9B**

Subject ID	ABCC3 Copy Number	CEP17 Copy Number	ABCC3/CEP17 Ratio	ABCC3 Amplification Status	Best Response (1=CR, 2=PR, 3=SD, 4=PD, 5=UE)	Confirmed Objective Response	FISH HER2 (30 or 60 Cell Count)	IHC Staining Intensity	HER2 RT-PCR Conc. Ratio to G6PDH
1	High	2.07	>7	Highly Amplified	4	4	Positive	3+	41.83
2	High	2.07	>7	Highly Amplified	2	2	Positive	3+	40.37
3	High	2.05	>7	Highly Amplified	2	2	Positive	2+	36.70
4	6.4	1.65	3.87	Amplified	3	3	Positive	1+	8.84
5	3.65	1.87	1.95	Amplified	3	3	Negative	2+	4.59
6	2.59	1.50	1.72	Normal	2	2	Negative	0	2.23
7	6.44	3.95	1.60	Cluster Amplification	4	4	Borderline	1+	2.32
8	4.17	2.67	1.56	Normal	2	2	Positive	1+	17.55
9	4.61	3.00	1.54	Normal	2	2	Positive	3+	38.04
10	3.71	2.54	1.46	Normal	2	2	Positive	2+	
11	3.81	2.65	1.43	Normal	2	2	Positive	0	5.69
12	6.35	4.50	1.41	Normal	2	2	Positive	1+	
13	2.93	2.11	1.38	Normal	2	2	Positive	3+	22.80
14	2.91	2.11	1.37	Normal	2	2	Positive	3+	6.24
15	4.47	3.73	1.19	Normal	2	2		3+	
16	3.91	3.39	1.15	Normal	2	2	Positive	1+	
17	2.77	2.56	1.08	Normal	2	2	Positive	1+	14.43
18	2.41	2.30	1.04	Normal	4	4	Positive	3+	14.65
19	2.41	2.36	1.02	Normal	2	2	Positive	3+	19.31
20	4.03	4.00	1.00	Normal	2	3	Positive	3+	33.92

CR=Complete Response; PR=Partial Response; SD=Stable Disease; PD=Progressive Disease; UE=Unevaluable
G6PDH=Glucose-6-phosphate Dehydrogenase

FIG. 10

FIG. 11**FIG. 11A****Molecular Subtype and Sensitivity to Anti-Mitotic Drugs**

Cell Line Designation:	Gene Expression Profiling Subtype	HER2 Copy number qPCR	Std. Dev.	Composite Molecular Subtype
BT549	Basal-like	1.7	0.1	Basal-like
CAL-120	Basal-like	2.2	0.4	Basal-like
CAL-51	Basal-like	2.5	0.0	Basal-like
CAL-85-1	Basal-like	1.2	0.0	Basal-like
DU4475	Basal-like	3.4	1.0	Basal-like
HCC-1143	Basal-like	1.8	0.1	Basal-like
HCC-70	Basal-like	1.0	0.0	Basal-like
HS 578T	Basal-like	4.5	0.2	Basal-like
MDA-MB-231	Basal-like	1.6	0.0	Basal-like
MDA-MB-435S	Basal-like	1.0	0.0	Basal-like
MDA-MB-436	Basal-like	1.0	0.0	Basal-like
MDA-MB-468	Basal-like	2.8	0.3	Basal-like
MT-3	Basal-like	2.0	0.2	Basal-like
AU565	Luminal	13.4	1.2	Her 2
BT474	Luminal	17.0	1.9	Her 2
EFM-192A	Luminal	28.5	0.9	Her 2
HCC-1419	Luminal	49.9	0.6	Her 2
HCC-2218	Luminal	81.2	0.9	Her 2
MDA-MB-361	Luminal	13.9	0.8	Her 2
MDA-MB-453	Luminal	8.0	0.2	Her 2
UACC-812	Luminal	12.4	4.8	Her 2
ZR-75-30	Luminal	31.2	0.4	Her 2
CAL-148	Basal-like	1.5	0.1	Luminal
CAMA-1	Luminal	3.3	0.4	Luminal
EFM-19	Luminal	2.8	0.6	Luminal
EVSA-T	Luminal	2.8	0.2	Luminal
HCC-1428	Luminal	1.0	0.0	Luminal
KPL-1	Luminal	1.9	0.2	Luminal
MCF-7	Luminal	1.3	0.1	Luminal
T47D	Luminal	2.1	0.1	Luminal
ZR-75-1	Luminal	1.3	0.0	Luminal

FIG. 11B

MMAE IC ₅₀ (nM) ¹	Std. Dev. MMAE ²	Paclitaxel IC ₅₀ (nM)	Std. Dev. Paclitaxel
4.6	2.2	5.5	14.1
17.2	4.8	11.4	12.4
1.3	2.1	12.8	7.6
2.1	4.1	1.7	9.2
1.5	3.9	133.6	31.8
>100	NA	7.4	5.8
1.1	5.6	17.9	11.3
0.9	0.3	42.5	29.3
38.9	6.0	9.8	8.6
0.6	0.4	1.0	1.0
1.9	0.6	>1000	NA
0.5	0.5	0.52	17.3
10.4	18.2	90.1	51.1
0.3	0.2	4.0	10.3
>100	NA	>1000	NA
>100	NA	>1000	NA
>100	NA	>1000	NA
>100	NA	>1000	NA
>100	NA	>1000	NA
>100	NA	>1000	NA
>100	NA	>1000	NA
>100	NA	>1000	NA
2.4	1.3	12.8	9.4
0.2	0.5	2.8	3.7
0.4	0.3	18.4	16.4
2.0	10.1	>1000	NA
>100	NA	>1000	NA
>100	NA	>1000	NA
2.7	4.5	0.1	1.2
>100	NA	0.1	1.2
>100	NA	>1000	NA

¹ >100 (MMAE), >1000 (paclitaxel) indicates IC₅₀ was not achieved in this cell line due to less than 50% inhibition of cell viability

² NA, Not applicable as cell line did not achieve IC₅₀

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- EP 404097 A [0042]
- WO 931161 A [0042]
- US 4816567 A [0044] [0045] [0093] [0095]
- WO 9824893 A [0044]
- WO 9634096 A [0044]
- WO 9633735 A [0044]
- WO 9110741 A [0044]
- US 5545807 A [0044] [0099]
- US 5545806 A [0044] [0099]
- US 5569825 A [0044] [0099]
- US 5625126 A [0044]
- US 5633425 A [0044]
- US 5661016 A [0044]
- WO 0042072 A, Presta [0053]
- US 5500362 A [0055]
- US 5821337 A [0055] [0123]
- US 6737056 B, Presta [0055]
- US 6194551 B1 [0057]
- WO 9951642 A [0057]
- US 5591669 A [0099]
- WO 9717852 A [0099]
- US 5565332 A [0100]
- US 5573905 A [0100]
- US 5567610 A [0101]
- US 5229275 A [0101]
- US 5869046 A [0103]
- WO 9316185 A [0103]
- US 5571894 A [0103]
- US 5587458 A [0103]
- US 5641870 A [0103]
- US 5739277 A [0104]
- US 5556762 A [0107]
- US 5750373 A [0107]
- US 4708871 A [0107]
- US 4833092 A [0107]
- US 5223409 A [0107] [0108]
- US 5403484 A [0107] [0108]
- US 5571689 A [0107] [0108]
- US 5663143 A [0107] [0108]
- WO 8403506 A [0107]
- WO 8403564 A [0107]
- US 5723286 A [0109]
- US 5432018 A [0109]
- US 5580717 A [0109]
- US 5427908 A [0109]
- US 5498530 A [0109]
- US 5770434 A [0109]
- US 5734018 A [0109]
- US 5698426 A [0109]
- US 5763192 A [0109]
- US 5723323 A [0109]
- WO 0000823 A [0110]
- WO 0039585 A [0110]
- US 3773919 A [0113]
- US 3896111 A [0116]
- US 4151042 A [0116]
- US 4137230 A [0116]
- US 4248870 A [0116]
- US 4256746 A [0116]
- US 4260608 A [0116]
- US 4265814 A [0116]
- US 4294757 A [0116]
- US 4307016 A [0116]
- US 4308268 A [0116]
- US 4308269 A [0116]
- US 4309428 A [0116]
- US 4313946 A [0116]
- US 4315929 A [0116]
- US 4317821 A [0116]
- US 4322348 A [0116]
- US 4331598 A [0116]
- US 4361650 A [0116]
- US 4364866 A [0116]
- US 4424219 A [0116]
- US 4450254 A [0116]
- US 4362663 A [0116]
- US 4371533 A [0116]
- US 5208020 A [0119] [0123]
- EP 0425235 B1 [0119]
- US 7097840 B [0122] [0123]
- US 20050276812 A [0122] [0123]
- WO 2004110498 A [0122]
- US 6441163 B [0123]
- US 20050166993 A [0123]

Non-patent literature cited in the description

- KIUCHI et al. *FEBS Lett.*, 1998, vol. 433, 149-152 [0017]
- BORST et al. *JNCI*, 2000, vol. 92 (16), 1295-1302 [0017]

- **PLUCKTHUN.** The Pharmacology of Monoclonal Antibodies. Springer-Verlag, 1994, vol. 113, 269-315 [0041]
- **HUDSON et al.** *Nat. Med.*, 2003, vol. 9, 129-134 [0042]
- **HOLLINGER et al.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 6444-6448 [0042]
- **KOHLER et al.** *Nature*, 1975, vol. 256, 495 [0044] [0093]
- **HARLOW et al.** Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1988 [0044]
- **HAMMERLING et al.** Monoclonal Antibodies and T-Cell Hybridomas. Elsevier, 1981, 563-681 [0044]
- **CLACKSON et al.** *Mature*, 1991, vol. 352, 624-628 [0044]
- **MARKS et al.** *J. Mol. Biol.*, 1992, vol. 222, 581-597 [0044]
- **SIDHU et al.** *J. Mol. Biol.*, 2004, vol. 338 (2), 299-310 [0044]
- **LEE et al.** *J. Mol. Biol.*, 2004, vol. 340 (5), 1073-1093 [0044]
- **FELLOUSE.** *Proc. Natl. Acad. Sci. USA*, 2004, vol. 101 (34), 12467-12472 [0044]
- **LEE et al.** *J. Immunol. Methods*, 2004, vol. 284 (1-2), 119-132 [0044]
- **JAKOBOVITS et al.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 2551 [0044] [0099]
- **JAKOBOVITS et al.** *Nature*, 1993, vol. 362, 255-258 [0044] [0099]
- **BRUGGEMANN et al.** *Year in Immunol*, 1993, vol. 7, 33 [0044]
- **MARKS et al.** *Bio. Technology*, 1992, vol. 10, 779-783 [0044]
- **LONBERG et al.** *Nature*, 1994, vol. 368, 856-859 [0044]
- **MORRISON.** *Nature*, 1994, vol. 368, 812-813 [0044]
- **FISHWILD et al.** *Nature Biotechnol.*, 1996, vol. 14, 845-851 [0044]
- **NEUBERGER.** *Nature Biotechnol.*, 1996, vol. 14, 826 [0044]
- **LONBERG ; HUSZAR.** *Intern. Rev. Immunol.*, 1995, vol. 13, 65-93 [0044]
- **MORRISON et al.** *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 6851-6855 [0045]
- **JONES et al.** *Nature*, 1986, vol. 321, 522-525 [0046] [0094] [0095]
- **RIECHMANN et al.** *Nature*, 1988, vol. 332, 323-329 [0046] [0094]
- **PRESTA.** *Curr. Op. Struct. Biol.*, 1992, vol. 2, 593-596 [0046] [0094]
- **VASWANI ; HAMILTON.** *Ann. Allergy, Asthma & Immunol.*, 1998, vol. 1, 105-115 [0046]
- **HARRIS.** *Biochem. Soc. Transactions*, 1995, vol. 23, 1035-1038 [0046]
- **HURLE ; GROSS.** *Curr. Op. Biotech.*, 1994, vol. 5, 428-433 [0046]
- **MARKS et al.** *J. Mol. Biol.*, 1991, vol. 222, 581-597 [0047] [0100]
- **HOOGENBOOM et al.** *Nucl. Acids Res.*, 1991, vol. 19, 4133-4137 [0047]
- **KOZBOR.** *J. Immunol.*, 1984, vol. 133, 3001 [0047]
- **BRODEUR et al.** Monoclonal Antibody Production Techniques and Applications. Marcel Dekker, Inc, 1987, 51-63 [0047]
- **BOERNER et al.** *J. Immunol.*, 1991, vol. 147, 86 [0047]
- **JAKOBOVITS et al.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 2551 [0047]
- **JAKOBOVITS et al.** *Nature*, 1993, vol. 362, 255 [0047]
- **BRUGGERMANN et al.** *Year in Immunol.*, 1993, vol. 7, 33 [0047]
- **MARKS et al.** *Bio/Technology*, 1992, vol. 10, 779-783 [0048]
- **BARBAS et al.** *Proc. Natl. Acad. Sci. USA*, 1994, vol. 91, 3809-3813 [0048]
- **SCHIER et al.** *Gene*, 1995, vol. 169, 147-155 [0048]
- **YELTON et al.** *J. Immunol.*, 1995, vol. 155, 1994-2004 [0048]
- **JACKSON et al.** *J. Immunol.*, 1995, vol. 154 (7), 3310-9 [0048]
- **HAWKINS et al.** *J. Mol. Biol.*, 1992, vol. 226, 889-896 [0048]
- **DAËRON.** *Annu. Rev. Immunol.*, 1997, vol. 15, 203-234 [0051]
- **RAVETCH ; KINET.** *Annu. Rev. Immunol*, 1991, vol. 9, 457-92 [0051] [0055]
- **CAPEL et al.** *Immunomethods*, 1994, vol. 4, 25-34 [0051]
- **DE HAAS et al.** *J. Lab. Clin. Med.*, 1995, vol. 126, 330-41 [0051]
- **GUYER et al.** *J. Immunol.*, 1976, vol. 117, 587 [0052]
- **KIM et al.** *J. Immunol.*, 1994, vol. 24, 249 [0052]
- **SHIELDS et al.** *J. Biol. Chem.*, 2001, vol. 9 (2), 6591-6604 [0053]
- **CLYNES.** *PNAS (USA)*, 1998, vol. 95, 652-656 [0055]
- **GAZZANO-SANTORO et al.** *J. Immunol. Methods*, 1996, vol. 202, 163 [0056]
- **IDUSOGIE et al.** *J. Immunol.*, 2000, vol. 164, 4178-4184 [0057]
- **CHEN, Y. et al.** *J. Mol. Biol.*, 1999, vol. 293, 865-881 [0064]
- **AVISON, M.** Measuring Gene Expression. Taylor & Francis Group, 2007 [0073]
- DNA Microarrays and Related Genomics Techniques: Design, Analysis, and Interpretation of Experiment (Biostatistics). Chapman & Hill/CRC, 2006 [0073]
- Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas. Elsevier Academic Press, 2004 [0073]
- **SNOUWAERT et al.** *Science*, 1992, vol. 257, 1083 [0091]
- **LOWELL et al.** *Nature*, 1993, vol. 366, 740-42 [0091]

- CAPECCHI, M. R. *Science*, 1989, vol. 244, 1288-1292 [0091]
- RIECHMANN et al. *Nature*, 1988, vol. 332, 323-327 [0095]
- VERHOEYEN et al. *Science*, 1988, vol. 239, 1534-1536 [0095]
- SIMS et al. *J. Immunol.*, 1993, vol. 151, 2296 [0096]
- CHOTHIA et al. *J. Mol. Biol.*, 1987, vol. 196, 901 [0096]
- CARTER et al. *Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 4285 [0096]
- PRESTA et al. *J. Immunol.*, 1993, vol. 151, 2623 [0096]
- BRUGGEMANN et al. *Year in Immuno.*, 1993, vol. 7, 33 [0099]
- MCCAFFERTY et al. *Nature*, 1990, vol. 348, 552-553 [0100]
- JOHNSON, KEVIN S. ; CHISWELL, DAVID J. *Current Opinion in Structural Biology*, 1993, vol. 3, 564-571 [0100]
- CLACKSON et al. *Nature*, 1991, vol. 352, 624-628 [0100]
- GRIFFITH et al. *EMBO J.*, 1993, vol. 12, 725-734 [0100]
- MORIMOTO et al. *Journal of Biochemical and Biophysical Methods*, 1992, vol. 24, 107-117 [0103]
- BRENNAN et al. *Science*, 1985, vol. 229, 81 [0103]
- CARTER et al. *BiolTechnology*, 1992, vol. 10, 163-167 [0103]
- Antibody Engineering [0103]
- CARON et al. *J. Exp Med.*, 1992, vol. 176, 1191-1195 [0104]
- SHOPES, B. *J. Immunol.*, 1992, vol. 148, 2918-2922 [0104]
- WOLFF et al. *Cancer Research*, 1993, vol. 53, 2560-2565 [0104]
- STEVENSON. *AntiCancer Drug Design*, 1989, vol. 3, 219-230 [0104]
- LEE et al. *Nucl. Acids Res.*, 1979, vol. 6, 3073 [0105]
- COONEY et al. *Science*, 1988, vol. 241, 456 [0105]
- DERVAN et al. *Science*, 1991, vol. 251, 1360 [0105]
- OKANO. *Neurochem*, 1991, vol. 56, 560 [0105]
- Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression. CRC Press, 1988 [0105]
- SHI Y. *Trends in Genetics*, 2003, vol. 19 (1), 9-12 [0106]
- FIRE A. *Trends in Genetics*, 1999, vol. 391, 806-810 [0106]
- GEYSEN et al. *Proc. Natl. Acad. Sci. U.S.A.*, 1984, vol. 81, 3998-4002 [0107]
- GEYSEN. *Proc. Natl. Acad. Sci. U.S.A.*, 1985, vol. 82, 178-182 [0107]
- GEYSEN. *Synthetic Peptides as Antigens*, 1986, 130-149 [0107]
- GEYSEN et al. *J. Immunol. Meth.*, 1987, vol. 102, 259-274 [0107]
- SCHOOF. *J. Immunol.*, 1988, vol. 140, 611-616 [0107]
- CWIRLA, S. E. et al. *Proc. Natl. Acad. Sci. USA*, 1990, vol. 87, 6378 [0107] [0108]
- LOWMAN, H.B. et al. *Biochemistry*, 1991, vol. 30, 10832 [0107] [0108]
- CLACKSON. T. *Nature*, 1991, vol. 352, 624 [0107]
- MARKS, J. D. et al. *J. Mol. Biol.*, 1991, vol. 222, 581 [0107]
- KANG, A.S et al. *Proc. Natl. Acad. Sci. USA*, 1991, vol. 88, 8363 [0107]
- SMITH, G. P. *Current Opin. Biotechnol.*, 1991, vol. 2, 668 [0107] [0108]
- SCOTT, J.K. ; SMITH, G. P. *Science*, 1990, vol. 249, 386 [0108]
- CLACKSON, T. et al. *Nature*, 1991, vol. 352, 624 [0108]
- MARKS, J. D. et al. *J. Mol. Biol.*, 1991, vol. 222, 581 [0108]
- KANG, A.S. et al. *Proc. Natl. Acad. Sci. USA*, 1991, vol. 88, 8363 [0108]
- Remington's Pharmaceutical Sciences. 1980 [0111]
- KAWAI et al. *Chem. Pharm. Bull.*, 1984, 3441-3451 [0116]
- PETTIT, G. R. The dolastatins. *Progress in the Chemistry of Organic Natural Products*, 1997, vol. 70, 1-79 [0117]
- CHARI et al. *Cancer Research*, 1992, vol. 52, 127-131 [0119]
- CARLSSON et al. *Biochem. J.*, 1978, vol. 173, 723-737 [0120]
- LAMBERT, J.M. *Current Opinion in Pharmacology*, 2005, vol. 5, 543-549 [0122]
- WUL, A. M. ; SENTER, P. D. *Nature Biotech*, 2005, vol. 23, 1137-1146 [0122]
- O'DRISCOLL L ; CLYNES M. Biomarkers and multiple drug resistance in breast cancer. *Curr Cancer Drug Targets*, 2006, vol. 6 (5), 365-84 [0155]
- CIGLER T ; GOSS PE. Breast cancer adjuvant endocrine therapy. *Cancer journal (Sudbury, Mass)*, 2007, vol. 13 (3), 148-55 [0155]
- SLAMON DJ ; LEYLAND-JONES B ; SHAK S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. *N Engl J Med*, 2001, vol. 344 (11), 783-92 [0155]
- GUARNERI V ; CONTE PF. The curability of breast cancer and the treatment of advanced disease. *Eur J Nucl Med Mol Imaging*, 2004, vol. 31 (1), 5149-61 [0155]
- SZAKACS G ; PATERSON JK ; LUDWIG JA ; BOOTH-GENTHE C ; GOTTESMAN MM. Targeting multidrug resistance in cancer. *Nature reviews*, 2006, vol. 5 (3), 219-34 [0155]
- KATSNELSON A. Cautious welcome for FDA pharmacogenomics guidance. *Nat Biotechnol*, 2005, vol. 23 (5), 510 [0155]

- **LEE JK ; HAVALESHKO DM ; CHO H et al.** A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. *Proc Natl Acad Sci U S A*, 2007, vol. 104 (32), 13086-91 [0155]
- **SZAKACS G ; ANNEREAU JP ; LABABIDI S et al.** Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. *Cancer Cell*, 2004, vol. 6 (2), 129-37 [0155]
- **SORLIE T ; TIBSHIRANI R ; PARKER J et al.** Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci U S A*, 2003, vol. 100 (14), 8418-23 [0155]
- **FINNEGAN TJ ; CAREY LA.** Gene-expression analysis and the basal-like breast cancer subtype. *Future Oncol*, 2007, vol. 3 (1), 55-63 [0155]
- **HU Z ; FAN C ; OH DS et al.** The molecular portraits of breast tumors are conserved across microarray platforms. *BMC Genomics*, 2006, vol. 7, 96 [0155]
- **KURT M ; HARPUTLUOGLU H ; DEDE DS ; GULLU IH ; ALTUNDAG K.** Potential molecular targeted therapies in the management of the basal-like subtype of breast cancer. *Breast*, 2007, vol. 16 (2), 111-2 [0155]
- **ROUZIER R ; PEROU CM ; SYMMANS WF et al.** Breast cancer molecular subtypes respond differently to preoperative chemotherapy. *Clin Cancer Res*, 2005, vol. 11 (16), 5678-85 [0155]
- **NEVE RM ; CHIN K ; FRIDLYAND J et al.** A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell*, 2006, vol. 10 (6), 515-27 [0155]
- **DORONINA SO ; TOKI BE ; TORGOMY MY et al.** Development of potent monoclonal antibody auristatin conjugates for cancer therapy. *Nat Biotechnol*, 2003, vol. 21 (7), 778-84 [0155]
- **CROWN J ; O'LEARY M.** The taxanes: an update. *Lancet*, 2000, vol. 355 (9210), 1176-8 [0155]
- **ZHAO X ; LI C ; PAEZ JG et al.** An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. *Cancer Res*, 2004, vol. 64 (9), 3060-71 [0155]
- **GARRAWAY LA ; WIDLUND HR ; RUBIN MA et al.** Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. *Nature*, 2005, vol. 436 (7047), 117-22 [0155]
- **GORRINGE KL ; CHIN SF ; PHAROAH P et al.** Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer. *Carcinogenesis*, 2005, vol. 26 (5), 923-30 [0155]
- **RAE JM ; RAMUS SJ ; WALTHAM M et al.** Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. *Clin Exp Metastasis*, 2004, vol. 21 (6), 543-52 [0155]
- **BARRETT MT ; SCHEFFER A ; BEN-DOR A et al.** Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. *Proc Natl Acad Sci USA*, 2004, vol. 101 (51), 17765-70 [0155]
- **EISEN MB ; SPELLMAN PT ; BROWN PO ; BOSTEIN D.** Cluster analysis and display of genome-wide expression patterns. *Proc Natl Acad Sci U S A*, 1998, vol. 95 (25), 14863-8 [0155]
- **MATSUZAKI H ; DONG S ; LOI H et al.** Genotyping over 100,000 SNPs on a pair of oligonucleotide arrays. *Nat Methods*, 2004, vol. 1 (2), 109-11 [0155]
- **HUPE P ; STRANSKY N ; THIERY JP ; RADVANYI F ; BARILLOT E.** Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. *Bioinformatics*, 2004, vol. 20 (18), 3413-22 [0155]
- **BEROUKHIM R ; GETZ G ; NGHIEMPHU L et al.** Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. *Proc Natl Acad Sci U S A*, 2007, vol. 104 (50), 20007-12 [0155]
- **WESTPHAL P ; YOUNG S.** Resampling-based multiple testing: Examples and methods for p-value adjustment. John Wiley & Sons, 1993 [0155]
- **FANNING TG ; SINGER MF.** LINE-1: a mammalian transposable element. *Biochimica et biophysica acta*, 1987, vol. 910 (3), 203-12 [0155]
- **KINDICH R ; FLORL AR ; JUNG V et al.** Application of a modified real-time PCR technique for relative gene copy number quantification to the determination of the relationship between NKX3.1 loss and MYC gain in prostate cancer. *Clin Chem*, 2005, vol. 51 (3), 649-52 [0155]
- **BAYANI J ; ZIELENSKA M ; MARRANO P et al.** Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. *J Neurosurg*, 2000, vol. 93 (3), 437-48 [0155]
- **GROVE LE ; GHOSH RN.** Quantitative characterization of mitosis-blocked tetraploid cells using high content analysis. *Assay and drug development technologies*, 2006, vol. 4 (4), 421-42 [0155]
- **LIVASY CA ; KARACA G ; NANDA R et al.** Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. *Mod Pathol*, 2006, vol. 19 (2), 264-71 [0155]
- **HU X SH ; O'BRIEN C ; HONCHELL ; WU T ; CHANT J ; LACKNER M ; CAVET G.** Genetic alterations and oncogenic pathways associated with breast cancer subtypes. *Molecular Cancer Research*, April 2009 [0155]
- **GASPARRI F ; CAPPELLA P ; GALVANI A.** Multiparametric cell cycle analysis by automated microscopy. *J Biomol Screen*, 2006, vol. 11 (6), 586-98 [0155]

- **BORST P ; EVERS R ; KOOL M ; WIJNHOLDS J.** A family of drug transporters: the multidrug resistance-associated proteins. *J Natl Cancer Inst*, 2000, vol. 92 (16), 1295-302 [0155]
- **CARLSSON J ; NORDGREN H ; SJOSTROM J et al.** HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. *Br J Cancer*, 2004, vol. 90 (12), 2344-8 [0155]
- **LIU Y ; PENG H ; ZHANG JT.** Expression profiling of ABC transporters in a drug-resistant breast cancer cell line using AmpArray. *Mol Pharmacol*, 2005, vol. 68 (2), 430-8 [0155]
- **HUANG R ; MURRY DJ ; KOLWANKAR D ; HALL SD ; FOSTER DR.** Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. *Biochem Pharmacol*, 2006, vol. 71 (12), 1695-704 [0155]
- **HUISMAN MT ; CHHATTA AA ; VAN TELLINGEN O ; BEIJNEN JH ; SCHINKEL AH.** MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. *Int J Cancer*, 2005, vol. 116 (5), 824-9 [0155]
- **HOPPER-BORGE E ; CHEN ZS ; SHCHAVELEVA I ; BELINSKY MG ; KRUH GD.** Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. *Cancer Res*, 2004, vol. 64 (14), 4927-30 [0155]
- **LAGAS JS ; VLAMING ML ; VAN TELLINGEN O et al.** Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. *Clin Cancer Res*, 2006, vol. 12 (20), 6125-32 [0155]
- **KOOL M ; VAN DER LINDEN M ; DE HAAS M et al.** MRP3, an organic anion transporter able to transport anti-cancer drugs. *Proc Natl Acad Sci U S A*, 1999, vol. 96 (12), 6914-9 [0155]
- **ZENG H ; BAIN LJ ; BELINSKY MG ; KRUH GD.** Expression of multidrug resistance protein-3 (multi-specific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anti-cancer agents. *Cancer Res*, 1999, vol. 59 (23), 5964-7 [0155]
- **MAHJOUBI F ; HILL RJ ; PETERS GB.** Chromosome microdissection identifies genomic amplifications associated with drug resistance in a leukemia cell line: an approach to understanding drug resistance in cancer. *Chromosome Res*, 2006, vol. 14 (3), 263-76 [0155]
- **SCHMIDT M ; BREMER E ; HASENCLEVER D et al.** Role of the progesterone receptor for paclitaxel resistance in primary breast cancer. *Br J Cancer*, 2007, vol. 96 (2), 241-7 [0155]
- **SHAJAHAN AN ; WANG A ; DECKER M ; MINSHALL RD ; LIU MC ; CLARKE R.** Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. *J Biol Chem*, 2006 [0155]
- **PINILLA SM ; HONRADO E ; HARDISSON D ; BENITEZ J ; PALACIOS J.** Cavcolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. *Breast Cancer Res Treat*, 2006, vol. 99 (1), 85-90 [0155]
- **SAVAGE K ; LAMBROS MB ; ROBERTSON D et al.** Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. *Clin Cancer Res*, 2007, vol. 13 (1), 90-101 [0155]
- **ROUZIER R ; RAJAN R ; WAGNER P et al.** Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. *Proc Natl Acad Sci U S A*, 2005, vol. 102 (23), 8315-20 [0155]
- **WAGNER P ; WANG B ; CLARKE E ; LEE H ; ROUZIER R ; PUSZTAI L.** Microtubule Associated Protein (MAP)-Tau: a novel mediator of Paclitaxel sensitivity in vitro and in vivo. *Cell Cycle*, 2005, vol. 4 (9), 1149-52 [0155]
- **LAMBROS MB ; NATRAJAN R ; REIS-FILHO JS.** Chromogenic and fluorescent in situ hybridization in breast cancer. *Hum Pathol*, 2007, vol. 38 (8), 1105-22 [0155]
- **HANN CL ; BRAHMER JR.** Who shouted receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?. *Curr Treat Options Oncol*, 2007, vol. 8 (1), 28-37 [0155]
- **HAYES DF ; THORAD ; DRESSLER LG et al.** HER2 and response to paclitaxel in node-positive breast cancer. *N Engl J Med*, 2007, vol. 357 (15), 1496-506 [0155]

9480D

EP 2 260 111

HATÓANYAGREZISZTENCIÁHOZ KAPCSOLÓDÓ GENETIKAI VARIÁCIÓK

Szabadalmi igénypontok

1. Eljárás annak meghatározására, hogy egy beteg emlőrákja rezisztens-e antimitotikus ágens – antitest konjugátummal történő kezelésre, amely konjugátum tartalmaz egy aurisztatin és egy majtanzinoid közül választott antimitotikus ágens, amely antitesthez kovalensen van kapcsolva, az eljárás során detektáljuk, hogy az ABCC3 gén amplifikálódik-e vagy túlexpresszálódik-e a beteg vizsgálati emlőrákmintájában, ahol az ABCC3 gén amplifikálódása vagy túlexpresszálódása azt jelzi, hogy az emlőrák rezisztens az antimitotikus ágens – antitest konjugátummal történő kezelésre.
2. Az 1. igénypont szerinti eljárás, amelynek során detektáljuk, hogy az ABCC3 gén amplifikálódik-e, ahol az ABCC3 gén amplifikálódásának detektálása során meghatározzuk az ABCC3 gén kópiaszámát, ahol egy legalább 3-as kópiaszám jelzi az ABCC3 gén amplifikálódását.
3. A 2. igénypont szerinti eljárás, ahol egy legalább 5-ös kópiaszám jelzi az ABCC3 gén amplifikálódását.
4. Az 1. igénypont szerinti eljárás, amelynek során detektáljuk, hogy az ABCC3 gén túlexpresszálódik-e, ahol az ABCC3 gén túlexpresszálódásának detektálása során meghatározzuk az ABCC3 génről történő mRNS transzkripció szintjét.
5. A 4. igénypont szerinti eljárás, ahol az ABCC3 gén túlexpresszálódását jelzi az, hogy az ABCC3 génről történő mRNS transzkripció szintje a vizsgálati rákmintában legalább 5-szörös egy kontroll mintához képest.

6. Az 5. igénypont szerinti eljárás, ahol az ABCC3 gén túlexpresszáldását jelzi az, hogy az ABCC3 génről történő mRNS transzkripció szintje a vizsgálati rákmintában legalább 25-szörös egy kontroll mintához képest.
7. Az 1. igénypont szerinti eljárás, amelynek során detektáljuk, hogy az ABCC3 gén túlexpresszáldik-e, ahol az ABCC3 gén túlexpresszáldásának detektálása során meghatározzuk az ABCC3 polipeptid expressziójának szintjét.
8. A 7. igénypont szerinti eljárás, ahol az ABCC3 polipeptid expressziós szintjének meghatározása során érintkeztetjük a vizsgálati emlőrákmintát egy anti-ABCC3 antitesttel és detektáljuk az anti-ABCC3 antitest kötődését ABCC3 polipeptidhez.
9. A 7. igénypont szerinti eljárás, ahol az ABCC3 gén túlexpresszáldását jelzi az, hogy az ABCC3 polipeptid expressziójának szintje a vizsgálati emlőrákmintában legalább 2-szeres egy kontroll mintához képest .
10. A 7. igénypont szerinti eljárás, ahol az ABCC3 gén túlexpresszáldását jelzi az, hogy az ABCC3 polipeptid expressziójának szintje a vizsgálati emlőrákmintában legalább 10-szeres egy kontroll mintához képest.
11. A 2. vagy 3. igénypont szerinti eljárás, ahol az ABCC3 gén kópiaszámának meghatározása fluoreszcens *in situ* hibridizációval (FISH), Southern Blottal, immunhisztokémiával (IHC), polimeráz-láncreakcióval (PCR), kvantitatív PCR-rel (qPCR), kvantitatív valósídejű PCR-rel (qRT-PCR), komparatív genomiális hibridizációval, mikromátrix-alapú komparatív genomiális hibridizációval, vagy ligáz-láncreakcióval (LCR) történik.
12. Az 1. igénypont szerinti eljárás, ahol az emlőrák Her2-pozitív emlőrák.
13. Az 1. igénypont szerinti eljárás, ahol az antimitotikus ágens:

- (a) egy aurisztatin, amelyet a monometil-aurisztatin-E (MMAE) és a monometil-aurisztatin-F (MMAF) által alkotott csoportból választunk; vagy
- (b) egy majtanzinoid, amelyet DM1 és DM4 által alkotott csoportból választunk.

14. Az 1. vagy a 13. igénypont szerinti eljárás, ahol az antimitotikus ágens – antitest konjugátum egy majtanzinoid-anti-Her2 antitest konjugátum.
15. A 14. igénypont szerinti eljárás, ahol a majtanzinoid-anti-Her2 antitest konjugátum trastuzumab-DM1.
16. Antimitotikus ágens – antitest konjugátum, amely tartalmaz egy aurisztatin és egy majtanzinoid közül választott antimitotikus ágens, amely antitesthez kovalensen van kapcsolva, olyan emlőrákban szenvedő beteg kezelésére szolgáló eljárásban történő alkalmazásra, amely rezisztens az antimitotikus ágens – antitest konjugátumra, amely eljárás során beadjuk a betegnek az ABCC3 egy antagonistáját és az antimitotikus ágens – antitest konjugátumot, ahol úgy került meghatározásra, hogy a beteg emlőrákja rezisztens az antimitotikus ágens – antitest konjugátumra, hogy detektáltuk, hogy az ABCC3 gén amplifikálódik vagy túlexpresszálódik a beteg egy vizsgálati emlőrákmintájában.
17. Az ABCC3 antagonistája olyan emlőrákban szenvedő beteg kezelésére szolgáló eljárásban történő alkalmazásra, amely rezisztens olyan antimitotikus ágens – antitest konjugátumra, amely tartalmaz egy aurisztatin és egy majtanzinoid közül választott antimitotikus ágens, amely antitesthez kovalensen van kapcsolva, amely eljárás során beadjuk a betegnek az ABCC3 egy antagonistáját és az antimitotikus ágens – antitest konjugátumot, ahol úgy került meghatározásra, hogy a beteg rákja rezisztens az antimitotikus ágens – antitest konjugátumra, hogy detektáltuk, hogy az ABCC3 gén amplifikálódik vagy túlexpresszálódik a beteg egy vizsgálati emlőrákmintájában.

18. Az antimitotikus ágens – antitest konjugátum alkalmazásra a 16. igénypont szerint vagy az ABCC3-antagonista alkalmazásra a 17. igénypont szerint, ahol az antagonistát a következők által alkotott csoportból választjuk: ABCC3-antitest és siRNS, amely kötődik az ABCC3-hoz.
19. Az antimitotikus ágens–antitest konjugátum alkalmazásra a 16. igénypont szerint vagy az ABCC3-antagonista alkalmazásra a 17. igénypont szerint, ahol az emlőrák Her2-pozitív emlőrák.
20. Antimitotikus ágens – antitest konjugátum, amely tartalmaz egy aurisztatin és egy majtanzinoid közül választott antimitotikus ágens, amely antitesthez kovalensen van kapcsolva, emlőrák kezelésére szolgáló eljárásban történő alkalmazásra, amely eljárás során
 - a) kiválasztunk egy beteget az alapján hogy a beteg rákjában nem amplifikálódik vagy expresszálódik túl az ABCC3, és
 - b) beadjuk a betegnek az antimitotikus ágens – antitest konjugátum terápiásan hatásos mennyiségét.
21. Az antimitotikus ágens – antitest konjugátum alkalmazásra a 20. igénypont szerint, ahol a kiválasztott betegnek Her2-pozitív emlőrákja van.
22. Az antimitotikus ágens – antitest konjugátum alkalmazásra a 20. vagy 21. igénypont szerint, ahol az antimitotikus ágens egy anti-Her2-antitest-antimitotikus ágens konjugátum.
23. Az antimitotikus ágens – antitest konjugátum alkalmazásra a 22. igénypont szerint, ahol az anti-Her2 antitest-antimitotikus ágens konjugátum trasztuzumab-DM1 vagy trasztuzumab-MMAE.
24. Az 1. igénypont szerinti eljárás annak meghatározására, hogy egy beteg emlőrákja rezisztens-e egy antimitotikus ágens – antitest konjugátummal történő kezelésre, amely antimitotikus ágens – antitest konjugátum

tartalmaz egy aurisztatin és egy majtanzinoid közül választott antimítotikus ágens, amely kovalensen trasztuzumabhoz van kapcsolva.

25. Az antimítotikus ágens – antitest konjugátum alkalmazásra a 16. igénypont szerint, amely tartalmaz egy aurisztatin és egy majtanzinoid közül választott antimítotikus ágens, amely trasztuzumabhoz kovalensen van kapcsolva.
26. Az ABCC3-antagonista alkalmazásra a 17. igénypont szerint, ahol az antimítotikus ágens – antitest konjugátum tartalmaz egy aurisztatin és egy majtanzinoid közül választott antimítotikus ágens, amely trasztuzumabhoz kovalensen van kapcsolva.
27. Az antimítotikus ágens – antitest konjugátum alkalmazásra a 20. igénypont szerint, amely antimítotikus ágens – antitest konjugátum tartalmaz egy aurisztatin és egy majtanzinoid közül választott antimítotikus ágens, amely trasztuzumabhoz kovalensen van kapcsolva.
28. Az 1. igénypont szerinti eljárás annak meghatározására, hogy egy beteg emlőrákja rezisztens-e egy antimítotikus ágens – antitest konjugátummal történő kezelésre, amely antimítotikus ágens – antitest konjugátum tartalmaz olyan antimítotikus ágens, amelyet monometil-aurisztatin-E (MMAE), monometil-aurisztatin-F (MMAF), DM1 és DM4 közül választunk.
29. Az antimítotikus ágens – antitest konjugátum alkalmazásra a 16. igénypont szerint, amely tartalmaz olyan antimítotikus ágens, amelyet monometil-aurisztatin-E (MMAE), monometil-aurisztatin-F (MMAF), DM1 és DM4 közül választunk.
30. Az ABCC3-antagonista alkalmazásra a 17. igénypont szerint, ahol az antimítotikus ágens – antitest konjugátum tartalmaz olyan antimítotikus ágens, amelyet monometil-aurisztatin-E (MMAE), monometil-aurisztatin-F (MMAF), DM1 és DM4 közül választunk.

31. Az antimitotikus ágens – antitest konjugátum alkalmazásra a 20. igénypont szerint, amely antimitotikus ágens – antitest konjugátum tartalmaz olyan antimitotikus ágens, amelyet monometil-aurisztatin-E (MMAE), monometil-aurisztatin-F (MMAF), DM1 és DM4 közül választunk.